In the last 12 months, insiders at Alkermes plc. ($ALKS) filed 840 transactions with the SEC: 0 open-market purchases totaling $0 and 40 sales totaling $27,812,507. Net insider sentiment: net selling.
Alkermes plc. operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Hopkinson Craig C. (EVP R&D, Chief Medical Officer) — 135 transactions totaling $38,101,764
- POPS RICHARD F (Director and CEO, Alkermes plc) — 26 transactions totaling $8,944,698
- Cooke Shane (Director) — 31 transactions totaling $4,349,313
- Nichols Christian Todd (SVP, Chief Commercial Officer) — 81 transactions totaling $4,020,509
- Jackson Blair Curtis (EVP, Chief Operating Officer) — 78 transactions totaling $2,719,132
View all SEC Filings for Alkermes plc. (ALKS).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 5000 | $19.34 | 94,389.0000 | 168,510,000 | 5.59% | 0.00% |
| April 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 9000 | $35.51 | 85,389.0000 | 168,510,000 | 9.54% | 0.01% |
| April 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 5000 | $0.00 | 16,356.0000 | 168,510,000 | 23.41% | 0.00% |
| March 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 5000 | $0.00 | 21,356.0000 | 168,510,000 | 18.97% | 0.00% |
| March 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 9000 | $29.72 | 89,389.0000 | 168,510,000 | 9.15% | 0.01% |
| March 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 5000 | $19.34 | 98,389.0000 | 168,510,000 | 5.35% | 0.00% |
| March 2, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | A | Restricted Stock Unit Award | 44078 | $0.00 | 44,078.0000 | 168,510,000 | 9999.99% | 0.03% |
| March 2, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | A | Employee Stock Option (Right to Buy) | 94900 | $0.00 | 94,900.0000 | 168,510,000 | 9999.99% | 0.06% |
| March 2, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | A | Restricted Stock Unit Award | 30854 | $0.00 | 30,854.0000 | 168,510,000 | 9999.99% | 0.02% |
| March 2, 2026 | Reed Joshua | SVP, Chief Financial Officer | A | Employee Stock Option (Right to Buy) | 66430 | $0.00 | 66,430.0000 | 168,510,000 | 9999.99% | 0.04% |
| March 2, 2026 | Reed Joshua | SVP, Chief Financial Officer | A | Restricted Stock Unit Award | 30854 | $0.00 | 30,854.0000 | 168,510,000 | 9999.99% | 0.02% |
| March 2, 2026 | POPS RICHARD F | Director and CEO, Alkermes plc | A | Restricted Stock Unit Award | 88843 | $0.00 | 88,843.0000 | 168,510,000 | 9999.99% | 0.05% |
| March 2, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | S | Ordinary Shares | 6890 | $29.29 | 7,717.0000 | 168,510,000 | 47.17% | 0.00% |
| March 2, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | A | Employee Stock Option (Right to Buy) | 15033 | $0.00 | 15,033.0000 | 168,510,000 | 9999.99% | 0.01% |
| March 2, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | A | Employee Stock Option (Right to Buy) | 66430 | $0.00 | 66,430.0000 | 168,510,000 | 9999.99% | 0.04% |
| March 2, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | S | Ordinary Shares | 6000 | $30.00 | 109,769.0000 | 168,510,000 | 5.18% | 0.00% |
| March 2, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | A | Restricted Stock Unit Award | 14176 | $0.00 | 14,176.0000 | 168,510,000 | 9999.99% | 0.01% |
| March 2, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | A | Restricted Stock Unit Award | 36364 | $0.00 | 36,364.0000 | 168,510,000 | 9999.99% | 0.02% |
| March 2, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | A | Employee Stock Option (Right to Buy) | 78292 | $0.00 | 78,292.0000 | 168,510,000 | 9999.99% | 0.05% |
| March 2, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S | Ordinary Shares | 2034 | $29.29 | 237,660.0000 | 168,510,000 | 0.85% | 0.00% |
| March 3, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S | Ordinary Shares | 2034 | $29.76 | 235,626.0000 | 168,510,000 | 0.86% | 0.00% |
| March 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Restricted Stock Unit Award | 38568 | $0.00 | 38,568.0000 | 168,510,000 | 9999.99% | 0.02% |
| March 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Employee Stock Option (Right to Buy) | 83037 | $0.00 | 83,037.0000 | 168,510,000 | 9999.99% | 0.05% |
| Feb. 26, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 6866 | $0.00 | 13,732.0000 | 168,510,000 | 33.33% | 0.00% |
| Feb. 26, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Ordinary Shares | 2747 | $0.00 | 15,415.0000 | 168,510,000 | 21.68% | 0.00% |
| Feb. 26, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F | Ordinary Shares | 808 | $30.73 | 14,607.0000 | 168,510,000 | 5.24% | 0.00% |
| Feb. 26, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Restricted Stock Unit Award | 2747 | $0.00 | 5,493.0000 | 168,510,000 | 33.34% | 0.00% |
| Feb. 26, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 5410 | $0.00 | 118,172.0000 | 168,510,000 | 4.80% | 0.00% |
| Feb. 26, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 2403 | $30.73 | 115,769.0000 | 168,510,000 | 2.03% | 0.00% |
| Feb. 26, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 5410 | $0.00 | 10,819.0000 | 168,510,000 | 33.34% | 0.00% |
| Feb. 26, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 8322 | $0.00 | 245,003.0000 | 168,510,000 | 3.52% | 0.00% |
| Feb. 26, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 3695 | $30.73 | 241,308.0000 | 168,510,000 | 1.51% | 0.00% |
| Feb. 26, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 8322 | $0.00 | 16,645.0000 | 168,510,000 | 33.33% | 0.00% |
| Feb. 26, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 6866 | $0.00 | 96,438.0000 | 168,510,000 | 7.67% | 0.00% |
| Feb. 26, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3049 | $30.73 | 93,389.0000 | 168,510,000 | 3.16% | 0.00% |
| Feb. 26, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 6866 | $0.00 | 13,732.0000 | 168,510,000 | 33.33% | 0.00% |
| Feb. 26, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 6866 | $0.00 | 242,743.0000 | 168,510,000 | 2.91% | 0.00% |
| Feb. 26, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 3049 | $30.73 | 239,694.0000 | 168,510,000 | 1.26% | 0.00% |
| Feb. 23, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 8738 | $0.00 | 8,738.0000 | 168,510,000 | 50.00% | 0.01% |
| Feb. 23, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 3880 | $32.19 | 236,681.0000 | 168,510,000 | 1.61% | 0.00% |
| Feb. 23, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 8738 | $0.00 | 240,561.0000 | 168,510,000 | 3.77% | 0.01% |
| Feb. 23, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 6407 | $0.00 | 6,408.0000 | 168,510,000 | 50.00% | 0.00% |
| Feb. 23, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 2845 | $32.19 | 112,762.0000 | 168,510,000 | 2.46% | 0.00% |
| Feb. 23, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 6407 | $0.00 | 115,607.0000 | 168,510,000 | 5.87% | 0.00% |
| Feb. 23, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Restricted Stock Unit Award | 2283 | $0.00 | 2,284.0000 | 168,510,000 | 49.99% | 0.00% |
| Feb. 23, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F | Ordinary Shares | 672 | $32.19 | 12,668.0000 | 168,510,000 | 5.04% | 0.00% |
| Feb. 23, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Ordinary Shares | 2283 | $0.00 | 13,340.0000 | 168,510,000 | 20.65% | 0.00% |
| Feb. 23, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 7689 | $0.00 | 7,690.0000 | 168,510,000 | 50.00% | 0.00% |
| Feb. 23, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 3414 | $32.19 | 235,877.0000 | 168,510,000 | 1.43% | 0.00% |
| Feb. 23, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 7689 | $0.00 | 239,291.0000 | 168,510,000 | 3.32% | 0.00% |
| Feb. 23, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 7689 | $0.00 | 7,690.0000 | 168,510,000 | 50.00% | 0.00% |
| Feb. 23, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3414 | $32.19 | 89,572.0000 | 168,510,000 | 3.67% | 0.00% |
| Feb. 23, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 7689 | $0.00 | 92,986.0000 | 168,510,000 | 9.01% | 0.00% |
| Feb. 19, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F | Ordinary Shares | 979 | $32.00 | 11,057.0000 | 168,510,000 | 8.13% | 0.00% |
| Feb. 18, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F | Ordinary Shares | 706 | $32.02 | 9,045.0000 | 168,510,000 | 7.24% | 0.00% |
| Feb. 18, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Ordinary Shares | 2034 | $0.00 | 9,751.0000 | 168,510,000 | 26.36% | 0.00% |
| Feb. 19, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 7673 | $0.00 | 23,019.0000 | 168,510,000 | 25.00% | 0.00% |
| Feb. 18, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 6355 | $0.00 | 0.0000 | 168,510,000 | 100.00% | 0.00% |
| Feb. 19, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 3407 | $32.00 | 231,602.0000 | 168,510,000 | 1.45% | 0.00% |
| Feb. 19, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 7673 | $0.00 | 235,009.0000 | 168,510,000 | 3.38% | 0.00% |
| Feb. 18, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 2126 | $32.02 | 227,336.0000 | 168,510,000 | 0.93% | 0.00% |
| Feb. 18, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 6355 | $0.00 | 229,462.0000 | 168,510,000 | 2.85% | 0.00% |
| Feb. 19, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 7673 | $0.00 | 23,019.0000 | 168,510,000 | 25.00% | 0.00% |
| Feb. 18, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 8897 | $0.00 | 0.0000 | 168,510,000 | 100.00% | 0.01% |
| Feb. 19, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3407 | $32.00 | 85,297.0000 | 168,510,000 | 3.84% | 0.00% |
| Feb. 19, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 7673 | $0.00 | 88,704.0000 | 168,510,000 | 9.47% | 0.00% |
| Feb. 18, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3504 | $32.02 | 81,031.0000 | 168,510,000 | 4.15% | 0.00% |
| Feb. 18, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 8897 | $0.00 | 84,535.0000 | 168,510,000 | 11.76% | 0.01% |
| Feb. 19, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 9300 | $0.00 | 27,903.0000 | 168,510,000 | 25.00% | 0.01% |
| Feb. 18, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 8897 | $0.00 | 0.0000 | 168,510,000 | 100.00% | 0.01% |
| Feb. 19, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 4130 | $32.00 | 231,823.0000 | 168,510,000 | 1.75% | 0.00% |
| Feb. 19, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 9300 | $0.00 | 235,953.0000 | 168,510,000 | 4.10% | 0.01% |
| Feb. 18, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 3796 | $32.02 | 226,653.0000 | 168,510,000 | 1.65% | 0.00% |
| Feb. 18, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 8897 | $0.00 | 230,449.0000 | 168,510,000 | 4.02% | 0.01% |
| Feb. 19, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 6045 | $0.00 | 18,137.0000 | 168,510,000 | 25.00% | 0.00% |
| Feb. 18, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 6355 | $0.00 | 0.0000 | 168,510,000 | 100.00% | 0.00% |
| Feb. 19, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 2277 | $32.00 | 109,200.0000 | 168,510,000 | 2.04% | 0.00% |
| Feb. 19, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 6045 | $0.00 | 111,477.0000 | 168,510,000 | 5.73% | 0.00% |
| Feb. 18, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 1869 | $32.02 | 105,432.0000 | 168,510,000 | 1.74% | 0.00% |
| Feb. 18, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 6355 | $0.00 | 107,301.0000 | 168,510,000 | 6.30% | 0.00% |
| Feb. 19, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Restricted Stock Unit Award | 2991 | $0.00 | 8,974.0000 | 168,510,000 | 25.00% | 0.00% |
| Feb. 18, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Restricted Stock Unit Award | 2034 | $0.00 | 0.0000 | 168,510,000 | 100.00% | 0.00% |
| Feb. 19, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Ordinary Shares | 2991 | $0.00 | 12,036.0000 | 168,510,000 | 33.07% | 0.00% |
| Feb. 5, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | A | Ordinary Shares | 28810 | $0.00 | 230,178.0000 | 168,510,000 | 14.31% | 0.02% |
| Feb. 5, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 8626 | $33.55 | 221,552.0000 | 168,510,000 | 3.75% | 0.01% |
| Feb. 5, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Ordinary Shares | 25352 | $0.00 | 83,092.0000 | 168,510,000 | 43.91% | 0.02% |
| Feb. 5, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 7454 | $33.55 | 75,638.0000 | 168,510,000 | 8.97% | 0.00% |
| Feb. 5, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | A | Ordinary Shares | 25352 | $0.00 | 230,726.0000 | 168,510,000 | 12.34% | 0.02% |
| Feb. 5, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 7619 | $33.55 | 223,107.0000 | 168,510,000 | 3.30% | 0.00% |
| Feb. 5, 2026 | POPS RICHARD F | Director and CEO, Alkermes plc | A | Ordinary Shares | 149580 | $0.00 | 1,439,970.0000 | 168,510,000 | 11.59% | 0.09% |
| Feb. 5, 2026 | POPS RICHARD F | Director and CEO, Alkermes plc | F | Ordinary Shares | 62230 | $33.55 | 1,377,740.0000 | 168,510,000 | 4.32% | 0.04% |
| Feb. 5, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | A | Ordinary Shares | 21127 | $0.00 | 107,335.0000 | 168,510,000 | 24.51% | 0.01% |
| Feb. 5, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 6389 | $33.55 | 100,946.0000 | 168,510,000 | 5.95% | 0.00% |
| Feb. 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 5000 | $19.34 | 66,740.0000 | 168,510,000 | 8.10% | 0.00% |
| Feb. 2, 2026 | Cooke Shane | Director | M | Ordinary Shares | 61200 | $31.64 | 164,944.0000 | 168,510,000 | 58.99% | 0.04% |
| Feb. 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 5000 | $0.00 | 26,356.0000 | 168,510,000 | 15.95% | 0.00% |
| Feb. 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 4000 | $33.54 | 57,740.0000 | 168,510,000 | 6.48% | 0.00% |
| Feb. 2, 2026 | Cooke Shane | Director | S | Ordinary Shares | 32113 | $34.78 | 103,744.0000 | 168,510,000 | 23.64% | 0.02% |
| Feb. 2, 2026 | Cooke Shane | Director | M | Employee Stock Option (Right to Buy) | 61200 | $0.00 | 0.0000 | 168,510,000 | 100.00% | 0.04% |
| Feb. 2, 2026 | Cooke Shane | Director | S | Ordinary Shares | 29087 | $34.34 | 135,857.0000 | 168,510,000 | 17.63% | 0.02% |
| Feb. 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 5000 | $34.24 | 61,740.0000 | 168,510,000 | 7.49% | 0.00% |
| Jan. 8, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 5000 | $30.00 | 61,740.0000 | 168,510,000 | 7.49% | 0.00% |
| Jan. 8, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 5000 | $0.00 | 31,356.0000 | 168,510,000 | 13.75% | 0.00% |
| Jan. 8, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 5000 | $19.34 | 66,740.0000 | 168,510,000 | 8.10% | 0.00% |
| Jan. 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 4000 | $28.00 | 61,740.0000 | 168,510,000 | 6.08% | 0.00% |
| Dec. 3, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 3748 | $19.34 | 69,488.0000 | 168,510,000 | 5.70% | 0.00% |
| Dec. 3, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 3748 | $0.00 | 36,356.0000 | 168,510,000 | 9.35% | 0.00% |
| Dec. 3, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 3748 | $30.00 | 65,740.0000 | 168,510,000 | 5.39% | 0.00% |
| Dec. 1, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 4000 | $29.30 | 65,740.0000 | 168,510,000 | 5.74% | 0.00% |
| Nov. 3, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 5000 | $19.34 | 78,740.0000 | 168,510,000 | 6.78% | 0.00% |
| Nov. 3, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 9000 | $30.38 | 69,740.0000 | 168,510,000 | 11.43% | 0.01% |
| Nov. 3, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 5000 | $0.00 | 40,104.0000 | 168,510,000 | 11.09% | 0.00% |
| Oct. 15, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 5000 | $0.00 | 45,104.0000 | 168,510,000 | 9.98% | 0.00% |
| Oct. 15, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 5000 | $19.34 | 82,740.0000 | 168,510,000 | 6.43% | 0.00% |
| Oct. 15, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 9000 | $31.53 | 73,740.0000 | 168,510,000 | 10.88% | 0.01% |
| Oct. 8, 2025 | Reed Joshua | SVP, Chief Financial Officer | A | Employee Stock Option (Right to Buy) | 158743 | $0.00 | 158,743.0000 | 168,510,000 | 9999.99% | 0.09% |
| Oct. 8, 2025 | Reed Joshua | SVP, Chief Financial Officer | A | Restricted Stock Unit Award | 36656 | $0.00 | 36,656.0000 | 168,510,000 | 9999.99% | 0.02% |
| Aug. 3, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 2014 | $0.00 | 2,015.0000 | 169,198,000 | 49.99% | 0.00% |
| Aug. 3, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 2014 | $0.00 | 206,269.0000 | 169,198,000 | 0.99% | 0.00% |
| Aug. 3, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 895 | $26.55 | 205,374.0000 | 169,198,000 | 0.43% | 0.00% |
| June 8, 2025 | Wright Christopher I | Director | M | Ordinary Shares | 3301 | $0.00 | 23,806.0000 | 169,198,000 | 16.10% | 0.00% |
| June 8, 2025 | Wright Christopher I | Director | F | Ordinary Shares | 793 | $31.71 | 23,013.0000 | 169,198,000 | 3.33% | 0.00% |
| June 8, 2025 | Wright Christopher I | Director | M | Restricted Stock Unit Award | 3301 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| June 9, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | S | Ordinary Shares | 3333 | $31.95 | 89,542.0000 | 169,198,000 | 3.59% | 0.00% |
| June 10, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | S | Ordinary Shares | 3334 | $31.09 | 86,208.0000 | 169,198,000 | 3.72% | 0.00% |
| May 31, 2025 | Wright Christopher I | Director | M | Restricted Stock Unit Award | 8013 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| May 31, 2025 | Wilson Frank Anders | Director | M | Ordinary Shares | 8013 | $0.00 | 33,008.0000 | 169,198,000 | 32.06% | 0.00% |
| May 31, 2025 | Wilson Frank Anders | Director | F | Ordinary Shares | 1924 | $30.61 | 31,084.0000 | 169,198,000 | 5.83% | 0.00% |
| May 31, 2025 | Wilson Frank Anders | Director | M | Restricted Stock Unit Award | 8013 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| May 31, 2025 | snyderman nancy lynn MD | Director | M | Ordinary Shares | 8013 | $0.00 | 33,435.0000 | 169,198,000 | 31.52% | 0.00% |
| May 31, 2025 | snyderman nancy lynn MD | Director | F | Ordinary Shares | 1924 | $30.61 | 31,511.0000 | 169,198,000 | 5.75% | 0.00% |
| May 31, 2025 | snyderman nancy lynn MD | Director | M | Restricted Stock Unit Award | 8013 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| May 31, 2025 | MCKEON BRIAN P | Director | M | Ordinary Shares | 8013 | $0.00 | 45,793.0000 | 169,198,000 | 21.21% | 0.00% |
| May 31, 2025 | MCKEON BRIAN P | Director | F | Ordinary Shares | 1924 | $30.61 | 43,869.0000 | 169,198,000 | 4.20% | 0.00% |
| May 31, 2025 | MCKEON BRIAN P | Director | M | Restricted Stock Unit Award | 8013 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| May 31, 2025 | Lurker Nancy | Director | M | Ordinary Shares | 8013 | $0.00 | 12,629.0000 | 169,198,000 | 173.59% | 0.00% |
| May 31, 2025 | Lurker Nancy | Director | F | Ordinary Shares | 1924 | $30.61 | 10,705.0000 | 169,198,000 | 15.23% | 0.00% |
| May 31, 2025 | Lurker Nancy | Director | M | Restricted Stock Unit Award | 8013 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| May 31, 2025 | LAURENCIN CATO T | Director | M | Ordinary Shares | 8013 | $0.00 | 31,026.0000 | 169,198,000 | 34.82% | 0.00% |
| May 31, 2025 | LAURENCIN CATO T | Director | F | Ordinary Shares | 1924 | $30.61 | 29,102.0000 | 169,198,000 | 6.20% | 0.00% |
| May 31, 2025 | LAURENCIN CATO T | Director | M | Restricted Stock Unit Award | 8013 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| May 31, 2025 | GAYNOR RICHARD | Director | M | Ordinary Shares | 8013 | $0.00 | 33,008.0000 | 169,198,000 | 32.06% | 0.00% |
| May 31, 2025 | GAYNOR RICHARD | Director | F | Ordinary Shares | 1924 | $30.61 | 31,084.0000 | 169,198,000 | 5.83% | 0.00% |
| May 31, 2025 | GAYNOR RICHARD | Director | M | Restricted Stock Unit Award | 8013 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| May 31, 2025 | Cooke Shane | Director | M | Ordinary Shares | 8013 | $0.00 | 107,919.0000 | 169,198,000 | 8.02% | 0.00% |
| May 31, 2025 | Cooke Shane | Director | F | Ordinary Shares | 4175 | $30.61 | 103,744.0000 | 169,198,000 | 3.87% | 0.00% |
| May 31, 2025 | Cooke Shane | Director | M | Restricted Stock Unit Award | 8013 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| May 31, 2025 | Wright Christopher I | Director | M | Ordinary Shares | 8013 | $0.00 | 22,429.0000 | 169,198,000 | 55.58% | 0.00% |
| May 31, 2025 | Wright Christopher I | Director | F | Ordinary Shares | 1924 | $30.61 | 20,505.0000 | 169,198,000 | 8.58% | 0.00% |
| May 21, 2025 | MCKEON BRIAN P | Director | A | Restricted Stock Unit Award | 6142 | $0.00 | 6,142.0000 | 169,198,000 | 9999.99% | 0.00% |
| May 21, 2025 | Lurker Nancy | Director | A | Non Qualified Stock Option (Right to Buy) | 13474 | $0.00 | 13,474.0000 | 169,198,000 | 9999.99% | 0.01% |
| May 21, 2025 | Lurker Nancy | Director | A | Restricted Stock Unit Award | 6142 | $0.00 | 6,142.0000 | 169,198,000 | 9999.99% | 0.00% |
| May 21, 2025 | LAURENCIN CATO T | Director | A | Non Qualified Stock Option (Right to Buy) | 13474 | $0.00 | 13,474.0000 | 169,198,000 | 9999.99% | 0.01% |
| May 21, 2025 | LAURENCIN CATO T | Director | A | Restricted Stock Unit Award | 6142 | $0.00 | 6,142.0000 | 169,198,000 | 9999.99% | 0.00% |
| May 21, 2025 | GAYNOR RICHARD | Director | A | Non Qualified Stock Option (Right to Buy) | 13474 | $0.00 | 13,474.0000 | 169,198,000 | 9999.99% | 0.01% |
| May 21, 2025 | GAYNOR RICHARD | Director | A | Restricted Stock Unit Award | 6142 | $0.00 | 6,142.0000 | 169,198,000 | 9999.99% | 0.00% |
| May 21, 2025 | Cooke Shane | Director | A | Non Qualified Stock Option (Right to Buy) | 13474 | $0.00 | 13,474.0000 | 169,198,000 | 9999.99% | 0.01% |
| May 21, 2025 | Cooke Shane | Director | A | Restricted Stock Unit Award | 6142 | $0.00 | 6,142.0000 | 169,198,000 | 9999.99% | 0.00% |
| May 21, 2025 | snyderman nancy lynn MD | Director | A | Non Qualified Stock Option (Right to Buy) | 13474 | $0.00 | 13,474.0000 | 169,198,000 | 9999.99% | 0.01% |
| May 21, 2025 | Wilson Frank Anders | Director | A | Restricted Stock Unit Award | 6142 | $0.00 | 6,142.0000 | 169,198,000 | 9999.99% | 0.00% |
| May 21, 2025 | Wilson Frank Anders | Director | A | Non Qualified Stock Option (Right to Buy) | 13474 | $0.00 | 13,474.0000 | 169,198,000 | 9999.99% | 0.01% |
| May 21, 2025 | Wright Christopher I | Director | A | Restricted Stock Unit Award | 6142 | $0.00 | 6,142.0000 | 169,198,000 | 9999.99% | 0.00% |
| May 21, 2025 | Wright Christopher I | Director | A | Non Qualified Stock Option (Right to Buy) | 13474 | $0.00 | 13,474.0000 | 169,198,000 | 9999.99% | 0.01% |
| May 21, 2025 | snyderman nancy lynn MD | Director | A | Restricted Stock Unit Award | 6142 | $0.00 | 6,142.0000 | 169,198,000 | 9999.99% | 0.00% |
| May 21, 2025 | MCKEON BRIAN P | Director | A | Non Qualified Stock Option (Right to Buy) | 13474 | $0.00 | 13,474.0000 | 169,198,000 | 9999.99% | 0.01% |
| April 11, 2025 | Lurker Nancy | Director | F | Ordinary Shares | 558 | $27.00 | 1,765.0000 | 169,198,000 | 24.02% | 0.00% |
| April 11, 2025 | Lurker Nancy | Director | M | Ordinary Shares | 3752 | $0.00 | 5,517.0000 | 169,198,000 | 212.58% | 0.00% |
| April 11, 2025 | Lurker Nancy | Director | F | Ordinary Shares | 901 | $27.00 | 4,616.0000 | 169,198,000 | 16.33% | 0.00% |
| April 11, 2025 | Lurker Nancy | Director | M | Restricted Stock Unit Award | 2323 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| April 11, 2025 | Lurker Nancy | Director | M | Restricted Stock Unit Award | 3752 | $0.00 | 7,503.0000 | 169,198,000 | 33.34% | 0.00% |
| April 11, 2025 | Lurker Nancy | Director | M | Ordinary Shares | 2323 | $0.00 | 2,323.0000 | 169,198,000 | 9999.99% | 0.00% |
| Feb. 26, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 6866 | $0.00 | 80,789.0000 | 169,198,000 | 9.29% | 0.00% |
| Feb. 26, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3049 | $34.80 | 77,740.0000 | 169,198,000 | 3.77% | 0.00% |
| Feb. 26, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 6866 | $0.00 | 20,598.0000 | 169,198,000 | 25.00% | 0.00% |
| Feb. 26, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 6866 | $0.00 | 207,304.0000 | 169,198,000 | 3.43% | 0.00% |
| Feb. 26, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 3049 | $34.80 | 204,255.0000 | 169,198,000 | 1.47% | 0.00% |
| Feb. 26, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 6866 | $0.00 | 20,598.0000 | 169,198,000 | 25.00% | 0.00% |
| Feb. 26, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | M | Ordinary Shares | 5617 | $0.00 | 150,690.0000 | 169,198,000 | 3.87% | 0.00% |
| Feb. 26, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 2494 | $34.80 | 148,196.0000 | 169,198,000 | 1.66% | 0.00% |
| Feb. 26, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F | Ordinary Shares | 808 | $34.80 | 9,655.0000 | 169,198,000 | 7.72% | 0.00% |
| Feb. 26, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | M | Restricted Stock Unit Award | 5617 | $0.00 | 16,854.0000 | 169,198,000 | 25.00% | 0.00% |
| Feb. 26, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Ordinary Shares | 2746 | $0.00 | 10,463.0000 | 169,198,000 | 35.58% | 0.00% |
| Feb. 28, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | S | Ordinary Shares | 1938 | $34.00 | 7,717.0000 | 169,198,000 | 20.07% | 0.00% |
| Feb. 26, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 5409 | $0.00 | 95,277.0000 | 169,198,000 | 6.02% | 0.00% |
| Feb. 26, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Restricted Stock Unit Award | 2746 | $0.00 | 8,240.0000 | 169,198,000 | 25.00% | 0.00% |
| Feb. 26, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 2402 | $34.80 | 92,875.0000 | 169,198,000 | 2.52% | 0.00% |
| Feb. 26, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 5409 | $0.00 | 16,229.0000 | 169,198,000 | 25.00% | 0.00% |
| Feb. 26, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 8322 | $0.00 | 205,063.0000 | 169,198,000 | 4.23% | 0.00% |
| Feb. 26, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 3695 | $34.80 | 201,368.0000 | 169,198,000 | 1.80% | 0.00% |
| Feb. 26, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 8322 | $0.00 | 24,967.0000 | 169,198,000 | 25.00% | 0.00% |
| Feb. 22, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12279 | $0.00 | 75,100.0000 | 169,198,000 | 19.55% | 0.01% |
| Feb. 22, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 7432 | $0.00 | 199,463.0000 | 169,198,000 | 3.87% | 0.00% |
| Feb. 22, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 3300 | $35.32 | 196,163.0000 | 169,198,000 | 1.65% | 0.00% |
| Feb. 23, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 7689 | $0.00 | 203,852.0000 | 169,198,000 | 3.92% | 0.00% |
| Feb. 23, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 3414 | $35.32 | 200,438.0000 | 169,198,000 | 1.67% | 0.00% |
| Feb. 22, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 7432 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| Feb. 23, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 7689 | $0.00 | 15,379.0000 | 169,198,000 | 33.33% | 0.00% |
| Feb. 22, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 9694 | $0.00 | 196,188.0000 | 169,198,000 | 5.20% | 0.01% |
| Feb. 22, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 4305 | $35.32 | 191,883.0000 | 169,198,000 | 2.19% | 0.00% |
| Feb. 23, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 8738 | $0.00 | 200,621.0000 | 169,198,000 | 4.55% | 0.01% |
| Feb. 23, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 3880 | $35.32 | 196,741.0000 | 169,198,000 | 1.93% | 0.00% |
| Feb. 22, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 9694 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.01% |
| Feb. 23, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 8738 | $0.00 | 17,476.0000 | 169,198,000 | 33.33% | 0.01% |
| Feb. 22, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Ordinary Shares | 3114 | $0.00 | 10,831.0000 | 169,198,000 | 40.35% | 0.00% |
| Feb. 22, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F | Ordinary Shares | 983 | $35.32 | 9,848.0000 | 169,198,000 | 9.08% | 0.00% |
| Feb. 23, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Ordinary Shares | 2284 | $0.00 | 12,132.0000 | 169,198,000 | 23.19% | 0.00% |
| Feb. 23, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F | Ordinary Shares | 672 | $35.32 | 11,460.0000 | 169,198,000 | 5.54% | 0.00% |
| Feb. 25, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | S | Ordinary Shares | 3743 | $35.26 | 7,717.0000 | 169,198,000 | 32.66% | 0.00% |
| Feb. 22, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Restricted Stock Unit Award | 3114 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| Feb. 23, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Restricted Stock Unit Award | 2284 | $0.00 | 4,567.0000 | 169,198,000 | 33.34% | 0.00% |
| Feb. 22, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | M | Ordinary Shares | 7109 | $0.00 | 144,989.0000 | 169,198,000 | 5.16% | 0.00% |
| Feb. 22, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 3154 | $35.32 | 141,835.0000 | 169,198,000 | 2.18% | 0.00% |
| Feb. 23, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | M | Ordinary Shares | 5825 | $0.00 | 147,660.0000 | 169,198,000 | 4.11% | 0.00% |
| Feb. 23, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 2587 | $35.32 | 145,073.0000 | 169,198,000 | 1.75% | 0.00% |
| Feb. 22, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | M | Restricted Stock Unit Award | 7109 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| Feb. 23, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | M | Restricted Stock Unit Award | 5825 | $0.00 | 11,650.0000 | 169,198,000 | 33.33% | 0.00% |
| Feb. 22, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 7109 | $0.00 | 89,463.0000 | 169,198,000 | 8.63% | 0.00% |
| Feb. 22, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 3157 | $35.32 | 86,306.0000 | 169,198,000 | 3.53% | 0.00% |
| Feb. 23, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 6408 | $0.00 | 92,714.0000 | 169,198,000 | 7.42% | 0.00% |
| Feb. 23, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 2846 | $35.32 | 89,868.0000 | 169,198,000 | 3.07% | 0.00% |
| Feb. 22, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 7109 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| Feb. 23, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 6408 | $0.00 | 12,815.0000 | 169,198,000 | 33.34% | 0.00% |
| Feb. 22, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 5452 | $35.32 | 69,648.0000 | 169,198,000 | 7.26% | 0.00% |
| Feb. 23, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 7689 | $0.00 | 77,337.0000 | 169,198,000 | 11.04% | 0.00% |
| Feb. 23, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3414 | $35.32 | 73,923.0000 | 169,198,000 | 4.41% | 0.00% |
| Feb. 22, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 12279 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.01% |
| Feb. 23, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 7689 | $0.00 | 15,379.0000 | 169,198,000 | 33.33% | 0.00% |
| Feb. 19, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | A | Restricted Stock Unit Award | 24182 | $0.00 | 24,182.0000 | 169,198,000 | 9999.99% | 0.01% |
| Feb. 18, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 6354 | $0.00 | 194,853.0000 | 169,198,000 | 3.37% | 0.00% |
| Feb. 19, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Restricted Stock Unit Award | 30692 | $0.00 | 30,692.0000 | 169,198,000 | 9999.99% | 0.02% |
| Feb. 19, 2025 | POPS RICHARD F | Director and CEO, Alkermes plc | A | Employee Stock Option (Right to Buy) | 293921 | $0.00 | 293,921.0000 | 169,198,000 | 9999.99% | 0.17% |
| Feb. 18, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Restricted Stock Unit Award | 2033 | $0.00 | 2,034.0000 | 169,198,000 | 49.99% | 0.00% |
| Feb. 20, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | S | Ordinary Shares | 1327 | $35.69 | 7,717.0000 | 169,198,000 | 14.67% | 0.00% |
| Feb. 18, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F | Ordinary Shares | 706 | $35.90 | 9,044.0000 | 169,198,000 | 7.24% | 0.00% |
| Feb. 18, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Ordinary Shares | 2033 | $0.00 | 9,750.0000 | 169,198,000 | 26.34% | 0.00% |
| Feb. 19, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | A | Restricted Stock Unit Award | 11965 | $0.00 | 11,965.0000 | 169,198,000 | 9999.99% | 0.01% |
| Feb. 18, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 6354 | $0.00 | 84,223.0000 | 169,198,000 | 8.16% | 0.00% |
| Feb. 18, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 1869 | $35.90 | 82,354.0000 | 169,198,000 | 2.22% | 0.00% |
| Feb. 18, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 6354 | $0.00 | 6,355.0000 | 169,198,000 | 50.00% | 0.00% |
| Feb. 19, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | A | Employee Stock Option (Right to Buy) | 50417 | $0.00 | 50,417.0000 | 169,198,000 | 9999.99% | 0.03% |
| Feb. 19, 2025 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | A | Employee Stock Option (Right to Buy) | 12287 | $0.00 | 12,287.0000 | 169,198,000 | 9999.99% | 0.01% |
| Feb. 18, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 2822 | $35.90 | 192,031.0000 | 169,198,000 | 1.45% | 0.00% |
| Feb. 18, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 6354 | $0.00 | 6,355.0000 | 169,198,000 | 50.00% | 0.00% |
| Feb. 19, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | A | Employee Stock Option (Right to Buy) | 63991 | $0.00 | 63,991.0000 | 169,198,000 | 9999.99% | 0.04% |
| Feb. 19, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | A | Restricted Stock Unit Award | 30692 | $0.00 | 30,692.0000 | 169,198,000 | 9999.99% | 0.02% |
| Feb. 18, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | M | Ordinary Shares | 6354 | $0.00 | 139,749.0000 | 169,198,000 | 4.76% | 0.00% |
| Feb. 18, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 1869 | $35.90 | 137,880.0000 | 169,198,000 | 1.34% | 0.00% |
| Feb. 18, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | M | Restricted Stock Unit Award | 6354 | $0.00 | 6,355.0000 | 169,198,000 | 50.00% | 0.00% |
| Feb. 18, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 8896 | $0.00 | 190,444.0000 | 169,198,000 | 4.90% | 0.01% |
| Feb. 18, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 3950 | $35.90 | 186,494.0000 | 169,198,000 | 2.07% | 0.00% |
| Feb. 18, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 8896 | $0.00 | 8,897.0000 | 169,198,000 | 50.00% | 0.01% |
| Feb. 19, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | A | Employee Stock Option (Right to Buy) | 77565 | $0.00 | 77,565.0000 | 169,198,000 | 9999.99% | 0.05% |
| Feb. 19, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | A | Restricted Stock Unit Award | 37203 | $0.00 | 37,203.0000 | 169,198,000 | 9999.99% | 0.02% |
| Feb. 18, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 8896 | $0.00 | 66,771.0000 | 169,198,000 | 15.37% | 0.01% |
| Feb. 18, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3950 | $35.90 | 62,821.0000 | 169,198,000 | 5.92% | 0.00% |
| Feb. 18, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 8896 | $0.00 | 8,897.0000 | 169,198,000 | 50.00% | 0.01% |
| Feb. 19, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Employee Stock Option (Right to Buy) | 63991 | $0.00 | 63,991.0000 | 169,198,000 | 9999.99% | 0.04% |
| Feb. 13, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 35586 | $0.00 | 71,172.0000 | 169,198,000 | 33.33% | 0.02% |
| Feb. 13, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 108833 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.06% |
| Feb. 12, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 111630 | $0.00 | 50,104.0000 | 169,198,000 | 69.02% | 0.07% |
| Feb. 12, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 87566 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.05% |
| Feb. 13, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 108833 | $36.02 | 57,875.0000 | 169,198,000 | 65.28% | 0.06% |
| Feb. 13, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 35586 | $34.02 | 166,708.0000 | 169,198,000 | 17.59% | 0.02% |
| Feb. 13, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 35586 | $24.59 | 202,294.0000 | 169,198,000 | 21.35% | 0.02% |
| Feb. 13, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 108833 | $31.93 | 166,708.0000 | 169,198,000 | 188.05% | 0.06% |
| Feb. 12, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 33108 | $33.27 | 57,875.0000 | 169,198,000 | 36.39% | 0.02% |
| Feb. 12, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 171813 | $32.69 | 90,983.0000 | 169,198,000 | 65.38% | 0.10% |
| Feb. 12, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 87566 | $20.03 | 151,166.0000 | 169,198,000 | 137.68% | 0.05% |
| Feb. 12, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 111630 | $19.34 | 262,796.0000 | 169,198,000 | 73.85% | 0.07% |
| Feb. 6, 2025 | POPS RICHARD F | Director and CEO, Alkermes plc | F | Ordinary Shares | 79925 | $31.39 | 1,290,390.0000 | 169,198,000 | 5.83% | 0.05% |
| Feb. 6, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 7514 | $31.39 | 133,395.0000 | 169,198,000 | 5.33% | 0.00% |
| Feb. 6, 2025 | Brown Iain Michael | SVP, Chief Financial Officer | A | Ordinary Shares | 24565 | $0.00 | 140,909.0000 | 169,198,000 | 21.11% | 0.01% |
| Feb. 6, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 9752 | $31.39 | 188,499.0000 | 169,198,000 | 4.92% | 0.01% |
| Feb. 6, 2025 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | A | Ordinary Shares | 32350 | $0.00 | 198,251.0000 | 169,198,000 | 19.50% | 0.02% |
| Feb. 6, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 15083 | $31.39 | 63,600.0000 | 169,198,000 | 19.17% | 0.01% |
| Feb. 6, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Ordinary Shares | 34393 | $0.00 | 78,683.0000 | 169,198,000 | 77.65% | 0.02% |
| Feb. 6, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 10647 | $31.39 | 181,548.0000 | 169,198,000 | 5.54% | 0.01% |
| Feb. 6, 2025 | Jackson Blair Curtis | EVP, Chief Operating Officer | A | Ordinary Shares | 34393 | $0.00 | 192,195.0000 | 169,198,000 | 21.80% | 0.02% |
| Feb. 6, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 7399 | $31.39 | 77,869.0000 | 169,198,000 | 8.68% | 0.00% |
| Feb. 6, 2025 | Nichols Christian Todd | SVP, Chief Commercial Officer | A | Ordinary Shares | 24565 | $0.00 | 85,268.0000 | 169,198,000 | 40.47% | 0.01% |
| Feb. 6, 2025 | POPS RICHARD F | Director and CEO, Alkermes plc | A | Ordinary Shares | 190640 | $0.00 | 1,370,315.0000 | 169,198,000 | 16.16% | 0.11% |
| Jan. 30, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 29156 | $20.03 | 76,732.0000 | 169,198,000 | 61.28% | 0.02% |
| Jan. 30, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 26589 | $19.34 | 103,321.0000 | 169,198,000 | 34.65% | 0.02% |
| Jan. 30, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 23542 | $24.59 | 126,863.0000 | 169,198,000 | 22.79% | 0.01% |
| Jan. 30, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 18345 | $26.82 | 145,208.0000 | 169,198,000 | 14.46% | 0.01% |
| Jan. 30, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 100918 | $32.05 | 44,290.0000 | 169,198,000 | 69.50% | 0.06% |
| Jan. 30, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 29156 | $0.00 | 87,566.0000 | 169,198,000 | 24.98% | 0.02% |
| Jan. 30, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 26589 | $0.00 | 161,734.0000 | 169,198,000 | 14.12% | 0.02% |
| Jan. 30, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 23542 | $0.00 | 106,758.0000 | 169,198,000 | 18.07% | 0.01% |
| Jan. 30, 2025 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 18345 | $0.00 | 92,271.0000 | 169,198,000 | 16.58% | 0.01% |
| Dec. 9, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12452 | $20.03 | 72,182.0000 | 170,196,000 | 20.85% | 0.01% |
| Dec. 9, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12090 | $19.34 | 84,272.0000 | 170,196,000 | 16.75% | 0.01% |
| Dec. 9, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12044 | $24.59 | 96,316.0000 | 170,196,000 | 14.29% | 0.01% |
| Dec. 9, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12411 | $26.82 | 108,727.0000 | 170,196,000 | 12.89% | 0.01% |
| Dec. 9, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 61151 | $32.07 | 47,576.0000 | 170,196,000 | 56.24% | 0.04% |
| Dec. 9, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 12452 | $0.00 | 116,722.0000 | 170,196,000 | 9.64% | 0.01% |
| Dec. 9, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 12090 | $0.00 | 188,323.0000 | 170,196,000 | 6.03% | 0.01% |
| Dec. 9, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 12044 | $0.00 | 130,300.0000 | 170,196,000 | 8.46% | 0.01% |
| Dec. 9, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 12411 | $0.00 | 110,616.0000 | 170,196,000 | 10.09% | 0.01% |
| Dec. 8, 2024 | LAURENCIN CATO T | Director | M | Ordinary Shares | 4163 | $0.00 | 23,971.0000 | 170,196,000 | 21.02% | 0.00% |
| Dec. 8, 2024 | LAURENCIN CATO T | Director | F | Ordinary Shares | 958 | $31.46 | 23,013.0000 | 170,196,000 | 4.00% | 0.00% |
| Dec. 9, 2024 | LAURENCIN CATO T | Director | M | Ordinary Shares | 2691 | $22.52 | 25,704.0000 | 170,196,000 | 11.69% | 0.00% |
| Dec. 9, 2024 | LAURENCIN CATO T | Director | S | Ordinary Shares | 2691 | $31.85 | 23,013.0000 | 170,196,000 | 10.47% | 0.00% |
| Dec. 8, 2024 | LAURENCIN CATO T | Director | M | Restricted Stock Unit Award | 4163 | $0.00 | 0.0000 | 170,196,000 | 100.00% | 0.00% |
| Dec. 9, 2024 | LAURENCIN CATO T | Director | M | Non Qualified Stock Option (Right to Buy) | 2691 | $0.00 | 16,142.0000 | 170,196,000 | 14.29% | 0.00% |
| Dec. 5, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 9221 | $31.50 | 59,730.0000 | 170,196,000 | 13.37% | 0.01% |
| Dec. 4, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 14349 | $30.77 | 68,951.0000 | 170,196,000 | 17.23% | 0.01% |
| Nov. 27, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | S | Ordinary Shares | 5208 | $29.15 | 60,703.0000 | 170,196,000 | 7.90% | 0.00% |
| Nov. 11, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 43058 | $20.03 | 142,296.0000 | 170,196,000 | 43.39% | 0.03% |
| Nov. 11, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 58996 | $30.08 | 83,300.0000 | 170,196,000 | 41.46% | 0.03% |
| Nov. 11, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 43058 | $0.00 | 129,174.0000 | 170,196,000 | 25.00% | 0.03% |
| Nov. 6, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 10471 | $29.53 | 99,238.0000 | 170,196,000 | 9.54% | 0.01% |
| Aug. 3, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 2014 | $0.00 | 4,029.0000 | 169,730,000 | 33.33% | 0.00% |
| Aug. 3, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 2014 | $0.00 | 166,796.0000 | 169,730,000 | 1.22% | 0.00% |
| Aug. 3, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 895 | $27.72 | 165,901.0000 | 169,730,000 | 0.54% | 0.00% |
| June 29, 2024 | Daglio David Angelo Jr. | Director | M | Ordinary Shares | 6104 | $0.00 | 109,245.0000 | 169,730,000 | 5.92% | 0.00% |
| June 29, 2024 | Daglio David Angelo Jr. | Director | M | Restricted Stock Unit Award | 6104 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| June 29, 2024 | Cooke Shane | Director | M | Ordinary Shares | 6104 | $0.00 | 103,081.0000 | 169,730,000 | 6.29% | 0.00% |
| June 29, 2024 | Cooke Shane | Director | F | Ordinary Shares | 3175 | $24.10 | 99,906.0000 | 169,730,000 | 3.08% | 0.00% |
| June 29, 2024 | Daglio David Angelo Jr. | Director | F | Ordinary Shares | 1465 | $24.10 | 107,780.0000 | 169,730,000 | 1.34% | 0.00% |
| June 29, 2024 | Alva Emily Peterson | Director | M | Restricted Stock Unit Award | 6104 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| June 29, 2024 | Cooke Shane | Director | M | Restricted Stock Unit Award | 6104 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| June 29, 2024 | Alva Emily Peterson | Director | M | Ordinary Shares | 6104 | $0.00 | 28,767.0000 | 169,730,000 | 26.93% | 0.00% |
| June 29, 2024 | Alva Emily Peterson | Director | F | Ordinary Shares | 1465 | $24.10 | 27,302.0000 | 169,730,000 | 5.09% | 0.00% |
| June 29, 2024 | Wright Christopher I | Director | M | Ordinary Shares | 6104 | $0.00 | 15,881.0000 | 169,730,000 | 62.43% | 0.00% |
| June 29, 2024 | Wright Christopher I | Director | F | Ordinary Shares | 1465 | $24.10 | 14,416.0000 | 169,730,000 | 9.22% | 0.00% |
| June 29, 2024 | Wright Christopher I | Director | M | Restricted Stock Unit Award | 6104 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| June 29, 2024 | Wilson Frank Anders | Director | M | Ordinary Shares | 6104 | $0.00 | 26,460.0000 | 169,730,000 | 29.99% | 0.00% |
| June 29, 2024 | Wilson Frank Anders | Director | F | Ordinary Shares | 1465 | $24.10 | 24,995.0000 | 169,730,000 | 5.54% | 0.00% |
| June 29, 2024 | Wilson Frank Anders | Director | M | Restricted Stock Unit Award | 6104 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| June 29, 2024 | snyderman nancy lynn MD | Director | M | Ordinary Shares | 6104 | $0.00 | 26,887.0000 | 169,730,000 | 29.37% | 0.00% |
| June 29, 2024 | snyderman nancy lynn MD | Director | F | Ordinary Shares | 1465 | $24.10 | 25,422.0000 | 169,730,000 | 5.45% | 0.00% |
| June 29, 2024 | snyderman nancy lynn MD | Director | M | Restricted Stock Unit Award | 6104 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| June 29, 2024 | MCKEON BRIAN P | Director | M | Ordinary Shares | 6104 | $0.00 | 39,245.0000 | 169,730,000 | 18.42% | 0.00% |
| June 29, 2024 | MCKEON BRIAN P | Director | F | Ordinary Shares | 1465 | $24.10 | 37,780.0000 | 169,730,000 | 3.73% | 0.00% |
| June 29, 2024 | MCKEON BRIAN P | Director | M | Restricted Stock Unit Award | 6104 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| June 29, 2024 | LAURENCIN CATO T | Director | M | Ordinary Shares | 6104 | $0.00 | 21,273.0000 | 169,730,000 | 40.24% | 0.00% |
| June 29, 2024 | LAURENCIN CATO T | Director | F | Ordinary Shares | 1465 | $24.10 | 19,808.0000 | 169,730,000 | 6.89% | 0.00% |
| June 29, 2024 | LAURENCIN CATO T | Director | M | Restricted Stock Unit Award | 6104 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| June 29, 2024 | GAYNOR RICHARD | Director | M | Ordinary Shares | 6104 | $0.00 | 26,460.0000 | 169,730,000 | 29.99% | 0.00% |
| June 29, 2024 | GAYNOR RICHARD | Director | F | Ordinary Shares | 1465 | $24.10 | 24,995.0000 | 169,730,000 | 5.54% | 0.00% |
| June 29, 2024 | GAYNOR RICHARD | Director | M | Restricted Stock Unit Award | 6104 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| June 8, 2024 | Wright Christopher I | Director | M | Restricted Stock Unit Award | 3301 | $0.00 | 3,301.0000 | 169,730,000 | 50.00% | 0.00% |
| June 9, 2024 | Alva Emily Peterson | Director | M | Restricted Stock Unit Award | 3871 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| June 8, 2024 | Wright Christopher I | Director | F | Ordinary Shares | 793 | $23.91 | 9,777.0000 | 169,730,000 | 7.50% | 0.00% |
| June 9, 2024 | Alva Emily Peterson | Director | F | Ordinary Shares | 930 | $23.91 | 22,663.0000 | 169,730,000 | 3.94% | 0.00% |
| June 9, 2024 | Alva Emily Peterson | Director | M | Ordinary Shares | 3871 | $0.00 | 23,593.0000 | 169,730,000 | 19.63% | 0.00% |
| June 8, 2024 | Wright Christopher I | Director | M | Ordinary Shares | 3301 | $0.00 | 10,570.0000 | 169,730,000 | 45.41% | 0.00% |
| Nov. 17, 2023 | GAYNOR RICHARD | Director | J | Non Qualified Stock Option (Right to Buy) | 256 | $16.52 | 13,079.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | GAYNOR RICHARD | Director | J | Non Qualified Stock Option (Right to Buy) | 224 | $20.81 | 11,424.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | GAYNOR RICHARD | Director | J | Non Qualified Stock Option (Right to Buy) | 1236 | $20.81 | 63,036.0000 | 163,742,000 | 2.00% | 0.00% |
| May 31, 2024 | LAURENCIN CATO T | Director | A | Non Qualified Stock Option (Right to Buy) | 17492 | $0.00 | 17,492.0000 | 169,730,000 | 9999.99% | 0.01% |
| May 31, 2024 | LAURENCIN CATO T | Director | A | Restricted Stock Unit Award | 8013 | $0.00 | 8,013.0000 | 169,730,000 | 9999.99% | 0.00% |
| May 31, 2024 | Lurker Nancy | Director | A | Non Qualified Stock Option (Right to Buy) | 17492 | $0.00 | 17,492.0000 | 169,730,000 | 9999.99% | 0.01% |
| May 31, 2024 | Lurker Nancy | Director | A | Restricted Stock Unit Award | 8013 | $0.00 | 8,013.0000 | 169,730,000 | 9999.99% | 0.00% |
| May 31, 2024 | MCKEON BRIAN P | Director | A | Non Qualified Stock Option (Right to Buy) | 17492 | $0.00 | 17,492.0000 | 169,730,000 | 9999.99% | 0.01% |
| May 31, 2024 | MCKEON BRIAN P | Director | A | Restricted Stock Unit Award | 8013 | $0.00 | 8,013.0000 | 169,730,000 | 9999.99% | 0.00% |
| May 31, 2024 | snyderman nancy lynn MD | Director | A | Non Qualified Stock Option (Right to Buy) | 17492 | $0.00 | 17,492.0000 | 169,730,000 | 9999.99% | 0.01% |
| May 31, 2024 | snyderman nancy lynn MD | Director | A | Restricted Stock Unit Award | 8013 | $0.00 | 8,013.0000 | 169,730,000 | 9999.99% | 0.00% |
| Nov. 17, 2023 | snyderman nancy lynn MD | Director | J | Restricted Stock Unit Award | 119 | $0.00 | 6,104.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 254 | $30.72 | 12,986.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 231 | $30.86 | 11,785.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 313 | $24.24 | 15,990.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 230 | $18.45 | 11,739.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 256 | $16.52 | 13,079.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 448 | $24.55 | 22,848.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 350 | $44.75 | 17,850.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 284 | $57.11 | 14,484.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 324 | $46.72 | 16,524.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 548 | $46.72 | 27,948.0000 | 163,742,000 | 2.00% | 0.00% |
| May 31, 2024 | Wilson Frank Anders | Director | A | Non Qualified Stock Option (Right to Buy) | 17492 | $0.00 | 17,492.0000 | 169,730,000 | 9999.99% | 0.01% |
| May 31, 2024 | Wilson Frank Anders | Director | A | Restricted Stock Unit Award | 8013 | $0.00 | 8,013.0000 | 169,730,000 | 9999.99% | 0.00% |
| Nov. 17, 2023 | Wilson Frank Anders | Director | J | Restricted Stock Unit Award | 119 | $0.00 | 6,104.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Wilson Frank Anders | Director | J | Non Qualified Stock Option (Right to Buy) | 254 | $30.72 | 12,986.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Wilson Frank Anders | Director | J | Non Qualified Stock Option (Right to Buy) | 231 | $30.86 | 11,785.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Wilson Frank Anders | Director | J | Non Qualified Stock Option (Right to Buy) | 313 | $24.24 | 15,990.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Wilson Frank Anders | Director | J | Non Qualified Stock Option (Right to Buy) | 230 | $18.45 | 11,739.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Wilson Frank Anders | Director | J | Non Qualified Stock Option (Right to Buy) | 256 | $16.52 | 13,079.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Wilson Frank Anders | Director | J | Non Qualified Stock Option (Right to Buy) | 1236 | $20.81 | 63,036.0000 | 163,742,000 | 2.00% | 0.00% |
| May 31, 2024 | Wright Christopher I | Director | A | Non Qualified Stock Option (Right to Buy) | 17492 | $0.00 | 17,492.0000 | 169,730,000 | 9999.99% | 0.01% |
| May 31, 2024 | Wright Christopher I | Director | A | Restricted Stock Unit Award | 8013 | $0.00 | 8,013.0000 | 169,730,000 | 9999.99% | 0.00% |
| Nov. 17, 2023 | Wright Christopher I | Director | J | Restricted Stock Unit Award | 119 | $0.00 | 6,104.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Wright Christopher I | Director | J | Non Qualified Stock Option (Right to Buy) | 254 | $30.72 | 12,986.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Wright Christopher I | Director | J | Non Qualified Stock Option (Right to Buy) | 231 | $30.86 | 11,785.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Wright Christopher I | Director | J | Restricted Stock Unit Award | 129 | $0.00 | 6,602.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Wright Christopher I | Director | J | Non Qualified Stock Option (Right to Buy) | 355 | $28.40 | 18,128.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Wright Christopher I | Director | J | Non Qualified Stock Option (Right to Buy) | 14 | $28.40 | 728.0000 | 163,742,000 | 1.96% | 0.00% |
| Nov. 17, 2023 | Wilson Frank Anders | Director | J | Non Qualified Stock Option (Right to Buy) | 224 | $20.81 | 11,424.0000 | 163,742,000 | 2.00% | 0.00% |
| May 31, 2024 | Alva Emily Peterson | Director | A | Non Qualified Stock Option (Right to Buy) | 17492 | $0.00 | 17,492.0000 | 169,730,000 | 9999.99% | 0.01% |
| May 31, 2024 | Alva Emily Peterson | Director | A | Restricted Stock Unit Award | 8013 | $0.00 | 8,013.0000 | 169,730,000 | 9999.99% | 0.00% |
| Nov. 17, 2023 | Alva Emily Peterson | Director | J | Restricted Stock Unit Award | 119 | $0.00 | 6,104.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Alva Emily Peterson | Director | J | Non Qualified Stock Option (Right to Buy) | 254 | $30.72 | 12,986.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Alva Emily Peterson | Director | J | Non Qualified Stock Option (Right to Buy) | 231 | $30.86 | 11,785.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alva Emily Peterson | Director | J | Non Qualified Stock Option (Right to Buy) | 313 | $24.24 | 15,990.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alva Emily Peterson | Director | J | Restricted Stock Unit Award | 75 | $0.00 | 3,871.0000 | 163,742,000 | 1.98% | 0.00% |
| Nov. 17, 2023 | Alva Emily Peterson | Director | J | Non Qualified Stock Option (Right to Buy) | 455 | $24.22 | 23,214.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alva Emily Peterson | Director | J | Non Qualified Stock Option (Right to Buy) | 22 | $24.22 | 1,137.0000 | 163,742,000 | 1.97% | 0.00% |
| May 31, 2024 | Cooke Shane | Director | A | Non Qualified Stock Option (Right to Buy) | 17492 | $0.00 | 17,492.0000 | 169,730,000 | 9999.99% | 0.01% |
| May 31, 2024 | Cooke Shane | Director | A | Restricted Stock Unit Award | 8013 | $0.00 | 8,013.0000 | 169,730,000 | 9999.99% | 0.00% |
| Nov. 17, 2023 | Cooke Shane | Director | J | Restricted Stock Unit Award | 119 | $0.00 | 6,104.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Cooke Shane | Director | J | Non Qualified Stock Option (Right to Buy) | 254 | $30.72 | 12,986.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Cooke Shane | Director | J | Non Qualified Stock Option (Right to Buy) | 231 | $30.86 | 11,785.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Cooke Shane | Director | J | Non Qualified Stock Option (Right to Buy) | 313 | $24.24 | 15,990.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Cooke Shane | Director | J | Non Qualified Stock Option (Right to Buy) | 230 | $18.45 | 11,739.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Cooke Shane | Director | J | Non Qualified Stock Option (Right to Buy) | 256 | $16.52 | 13,079.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Cooke Shane | Director | J | Non Qualified Stock Option (Right to Buy) | 448 | $24.55 | 22,848.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Cooke Shane | Director | J | Non Qualified Stock Option (Right to Buy) | 350 | $44.75 | 17,850.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Cooke Shane | Director | J | Non Qualified Stock Option (Right to Buy) | 520 | $44.75 | 26,520.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Cooke Shane | Director | J | Employee Stock Option (Right to Buy) | 425 | $53.50 | 21,675.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Cooke Shane | Director | J | Employee Stock Option (Right to Buy) | 1200 | $31.64 | 61,200.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Cooke Shane | Director | J | Employee Stock Option (Right to Buy) | 1102 | $69.83 | 56,227.0000 | 163,742,000 | 2.00% | 0.00% |
| May 31, 2024 | Daglio David Angelo Jr. | Director | A | Non Qualified Stock Option (Right to Buy) | 17492 | $0.00 | 17,492.0000 | 169,730,000 | 9999.99% | 0.01% |
| May 31, 2024 | Daglio David Angelo Jr. | Director | A | Restricted Stock Unit Award | 8013 | $0.00 | 8,013.0000 | 169,730,000 | 9999.99% | 0.00% |
| May 31, 2024 | GAYNOR RICHARD | Director | A | Non Qualified Stock Option (Right to Buy) | 17492 | $0.00 | 17,492.0000 | 169,730,000 | 9999.99% | 0.01% |
| May 31, 2024 | GAYNOR RICHARD | Director | A | Restricted Stock Unit Award | 8013 | $0.00 | 8,013.0000 | 169,730,000 | 9999.99% | 0.00% |
| Nov. 17, 2023 | GAYNOR RICHARD | Director | J | Restricted Stock Unit Award | 119 | $0.00 | 6,104.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | GAYNOR RICHARD | Director | J | Non Qualified Stock Option (Right to Buy) | 254 | $30.72 | 12,986.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | GAYNOR RICHARD | Director | J | Non Qualified Stock Option (Right to Buy) | 231 | $30.86 | 11,785.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | GAYNOR RICHARD | Director | J | Non Qualified Stock Option (Right to Buy) | 313 | $24.24 | 15,990.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | GAYNOR RICHARD | Director | J | Non Qualified Stock Option (Right to Buy) | 230 | $18.45 | 11,739.0000 | 163,742,000 | 2.00% | 0.00% |
| April 11, 2024 | Lurker Nancy | Director | A | Restricted Stock Unit Award | 2323 | $0.00 | 2,323.0000 | 169,730,000 | 9999.99% | 0.00% |
| April 11, 2024 | Lurker Nancy | Director | A | Non Qualified Stock Option (Right to Buy) | 4833 | $0.00 | 4,833.0000 | 169,730,000 | 9999.99% | 0.00% |
| April 11, 2024 | Lurker Nancy | Director | A | Restricted Stock Unit Award | 11255 | $0.00 | 11,255.0000 | 169,730,000 | 9999.99% | 0.01% |
| April 11, 2024 | Lurker Nancy | Director | A | Non Qualified Stock Option (Right to Buy) | 22103 | $0.00 | 22,103.0000 | 169,730,000 | 9999.99% | 0.01% |
| March 18, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | S | Ordinary Shares | 10417 | $28.10 | 65,911.0000 | 169,730,000 | 13.65% | 0.01% |
| Feb. 26, 2024 | POPS RICHARD F | Director and CEO, Alkermes plc | A | Employee Stock Option (Right to Buy) | 274328 | $0.00 | 274,328.0000 | 169,730,000 | 9999.99% | 0.16% |
| Nov. 17, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | J | Employee Stock Option (Right to Buy) | 5697 | $26.82 | 290,570.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | J | Employee Stock Option (Right to Buy) | 5980 | $24.59 | 305,024.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | J | Employee Stock Option (Right to Buy) | 6843 | $19.34 | 349,030.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | J | Employee Stock Option (Right to Buy) | 7168 | $20.03 | 365,634.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | J | Employee Stock Option (Right to Buy) | 7644 | $31.93 | 389,844.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | J | Employee Stock Option (Right to Buy) | 2419 | $31.93 | 123,419.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | J | Employee Stock Option (Right to Buy) | 5899 | $65.94 | 300,899.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | J | Employee Stock Option (Right to Buy) | 3999 | $53.50 | 203,999.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | J | Employee Stock Option (Right to Buy) | 5999 | $31.64 | 305,999.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | J | Employee Stock Option (Right to Buy) | 3999 | $69.83 | 203,999.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | J | Employee Stock Option (Right to Buy) | 4599 | $46.24 | 234,599.0000 | 163,742,000 | 2.00% | 0.00% |
| Feb. 26, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Restricted Stock Unit Award | 27464 | $0.00 | 27,464.0000 | 169,730,000 | 9999.99% | 0.02% |
| Feb. 26, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Employee Stock Option (Right to Buy) | 111186 | $0.00 | 111,186.0000 | 169,730,000 | 9999.99% | 0.07% |
| Feb. 23, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 7689 | $0.00 | 23,068.0000 | 169,730,000 | 25.00% | 0.00% |
| Feb. 23, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3414 | $29.57 | 109,709.0000 | 169,730,000 | 3.02% | 0.00% |
| Feb. 23, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 7689 | $0.00 | 113,123.0000 | 169,730,000 | 7.29% | 0.00% |
| Feb. 26, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | A | Restricted Stock Unit Award | 33289 | $0.00 | 33,289.0000 | 169,730,000 | 9999.99% | 0.02% |
| Feb. 26, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | A | Employee Stock Option (Right to Buy) | 134771 | $0.00 | 134,771.0000 | 169,730,000 | 9999.99% | 0.08% |
| Feb. 23, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 8737 | $0.00 | 26,214.0000 | 169,730,000 | 25.00% | 0.01% |
| Feb. 23, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 3880 | $29.57 | 157,802.0000 | 169,730,000 | 2.40% | 0.00% |
| Feb. 23, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 8737 | $0.00 | 161,682.0000 | 169,730,000 | 5.71% | 0.01% |
| Feb. 23, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Restricted Stock Unit Award | 4077 | $0.00 | 12,233.0000 | 169,730,000 | 25.00% | 0.00% |
| Feb. 23, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | F | Ordinary Shares | 1811 | $29.57 | 281,730.0000 | 169,730,000 | 0.64% | 0.00% |
| Feb. 23, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Ordinary Shares | 4077 | $0.00 | 283,541.0000 | 169,730,000 | 1.46% | 0.00% |
| Feb. 26, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | A | Restricted Stock Unit Award | 27464 | $0.00 | 27,464.0000 | 169,730,000 | 9999.99% | 0.02% |
| Feb. 26, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | A | Employee Stock Option (Right to Buy) | 111186 | $0.00 | 111,186.0000 | 169,730,000 | 9999.99% | 0.07% |
| Feb. 23, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 7689 | $0.00 | 23,068.0000 | 169,730,000 | 25.00% | 0.00% |
| Feb. 23, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 3414 | $29.57 | 164,782.0000 | 169,730,000 | 2.03% | 0.00% |
| Feb. 23, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 7689 | $0.00 | 168,196.0000 | 169,730,000 | 4.79% | 0.00% |
| Feb. 26, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | A | Restricted Stock Unit Award | 22471 | $0.00 | 22,471.0000 | 169,730,000 | 9999.99% | 0.01% |
| Feb. 26, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | A | Employee Stock Option (Right to Buy) | 90971 | $0.00 | 90,971.0000 | 169,730,000 | 9999.99% | 0.05% |
| Feb. 23, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | M | Restricted Stock Unit Award | 5825 | $0.00 | 17,475.0000 | 169,730,000 | 25.00% | 0.00% |
| Feb. 23, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 2587 | $29.57 | 116,344.0000 | 169,730,000 | 2.18% | 0.00% |
| Feb. 23, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | M | Ordinary Shares | 5825 | $0.00 | 118,931.0000 | 169,730,000 | 5.15% | 0.00% |
| Feb. 26, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | A | Restricted Stock Unit Award | 10986 | $0.00 | 10,986.0000 | 169,730,000 | 9999.99% | 0.01% |
| Feb. 26, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | A | Employee Stock Option (Right to Buy) | 20890 | $0.00 | 20,890.0000 | 169,730,000 | 9999.99% | 0.01% |
| Feb. 23, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Restricted Stock Unit Award | 2283 | $0.00 | 6,851.0000 | 169,730,000 | 24.99% | 0.00% |
| Feb. 27, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | S | Ordinary Shares | 2559 | $29.65 | 7,717.0000 | 169,730,000 | 24.90% | 0.00% |
| Feb. 23, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F | Ordinary Shares | 672 | $29.57 | 10,276.0000 | 169,730,000 | 6.14% | 0.00% |
| Feb. 23, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Ordinary Shares | 2283 | $0.00 | 10,948.0000 | 169,730,000 | 26.35% | 0.00% |
| Feb. 26, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | A | Restricted Stock Unit Award | 21638 | $0.00 | 21,638.0000 | 169,730,000 | 9999.99% | 0.01% |
| Feb. 26, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | A | Employee Stock Option (Right to Buy) | 87602 | $0.00 | 87,602.0000 | 169,730,000 | 9999.99% | 0.05% |
| Feb. 23, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 6407 | $0.00 | 19,223.0000 | 169,730,000 | 25.00% | 0.00% |
| Feb. 23, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 2845 | $29.57 | 76,328.0000 | 169,730,000 | 3.59% | 0.00% |
| Feb. 23, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 6407 | $0.00 | 79,173.0000 | 169,730,000 | 8.80% | 0.00% |
| Feb. 22, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Restricted Stock Unit Award | 5654 | $0.00 | 5,655.0000 | 169,730,000 | 50.00% | 0.00% |
| Feb. 22, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Ordinary Shares | 3114 | $0.00 | 9,573.0000 | 169,730,000 | 48.21% | 0.00% |
| Feb. 22, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F | Ordinary Shares | 908 | $28.91 | 8,665.0000 | 169,730,000 | 9.49% | 0.00% |
| Feb. 22, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Restricted Stock Unit Award | 3114 | $0.00 | 3,114.0000 | 169,730,000 | 50.00% | 0.00% |
| Feb. 22, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 7108 | $0.00 | 75,922.0000 | 169,730,000 | 10.33% | 0.00% |
| Feb. 22, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 3156 | $28.91 | 72,766.0000 | 169,730,000 | 4.16% | 0.00% |
| Feb. 22, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 7108 | $0.00 | 7,109.0000 | 169,730,000 | 50.00% | 0.00% |
| Feb. 22, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Ordinary Shares | 5654 | $0.00 | 281,393.0000 | 169,730,000 | 2.05% | 0.00% |
| Feb. 22, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | F | Ordinary Shares | 1929 | $28.91 | 279,464.0000 | 169,730,000 | 0.69% | 0.00% |
| Feb. 22, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 9693 | $0.00 | 157,249.0000 | 169,730,000 | 6.57% | 0.01% |
| Feb. 22, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 4304 | $28.91 | 152,945.0000 | 169,730,000 | 2.74% | 0.00% |
| Feb. 22, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 9693 | $0.00 | 9,694.0000 | 169,730,000 | 50.00% | 0.01% |
| Feb. 22, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12278 | $0.00 | 110,886.0000 | 169,730,000 | 12.45% | 0.01% |
| Feb. 22, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 5452 | $28.91 | 105,434.0000 | 169,730,000 | 4.92% | 0.00% |
| Feb. 22, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 12278 | $0.00 | 12,279.0000 | 169,730,000 | 50.00% | 0.01% |
| Feb. 22, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 7431 | $0.00 | 163,807.0000 | 169,730,000 | 4.75% | 0.00% |
| Feb. 22, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 3300 | $28.91 | 160,507.0000 | 169,730,000 | 2.01% | 0.00% |
| Feb. 22, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 7431 | $0.00 | 7,432.0000 | 169,730,000 | 50.00% | 0.00% |
| Feb. 22, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | M | Ordinary Shares | 7108 | $0.00 | 116,262.0000 | 169,730,000 | 6.51% | 0.00% |
| Feb. 22, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 3156 | $28.91 | 113,106.0000 | 169,730,000 | 2.71% | 0.00% |
| Feb. 22, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | M | Restricted Stock Unit Award | 7108 | $0.00 | 7,109.0000 | 169,730,000 | 50.00% | 0.00% |
| Feb. 20, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Restricted Stock Unit Award | 5461 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Restricted Stock Unit Award | 319 | $0.00 | 16,310.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 1279 | $26.82 | 65,241.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Restricted Stock Unit Award | 261 | $0.00 | 13,345.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 1394 | $24.59 | 71,171.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Restricted Stock Unit Award | 221 | $0.00 | 11,309.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 1809 | $19.34 | 92,296.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Restricted Stock Unit Award | 107 | $0.00 | 5,461.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 1790 | $20.03 | 91,335.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 1811 | $31.93 | 92,411.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 1089 | $65.94 | 55,589.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 999 | $53.50 | 50,999.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 1519 | $31.64 | 77,519.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 879 | $69.83 | 44,879.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 999 | $46.24 | 50,999.0000 | 163,742,000 | 2.00% | 0.00% |
| Feb. 20, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | F | Ordinary Shares | 1606 | $30.39 | 275,739.0000 | 169,730,000 | 0.58% | 0.00% |
| Feb. 20, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Ordinary Shares | 5461 | $0.00 | 277,345.0000 | 169,730,000 | 2.01% | 0.00% |
| Feb. 18, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | F | Ordinary Shares | 1308 | $32.18 | 271,884.0000 | 169,730,000 | 0.48% | 0.00% |
| Feb. 18, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Ordinary Shares | 4448 | $0.00 | 273,192.0000 | 169,730,000 | 1.66% | 0.00% |
| Feb. 20, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 3901 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| Feb. 18, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 6355 | $0.00 | 12,709.0000 | 169,730,000 | 33.34% | 0.00% |
| Nov. 17, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | J | Restricted Stock Unit Award | 502 | $0.00 | 25,630.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | J | Employee Stock Option (Right to Buy) | 2010 | $26.82 | 102,522.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | J | Restricted Stock Unit Award | 373 | $0.00 | 19,064.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | J | Employee Stock Option (Right to Buy) | 1992 | $24.59 | 101,674.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | J | Restricted Stock Unit Award | 278 | $0.00 | 14,217.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | J | Employee Stock Option (Right to Buy) | 2274 | $19.34 | 116,028.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | J | Restricted Stock Unit Award | 76 | $0.00 | 3,901.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | J | Employee Stock Option (Right to Buy) | 885 | $20.03 | 45,212.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | J | Employee Stock Option (Right to Buy) | 999 | $22.94 | 50,999.0000 | 163,742,000 | 2.00% | 0.00% |
| Feb. 20, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 1379 | $30.39 | 68,814.0000 | 169,730,000 | 1.96% | 0.00% |
| Feb. 20, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 3901 | $0.00 | 70,193.0000 | 169,730,000 | 5.88% | 0.00% |
| Feb. 18, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 1869 | $32.18 | 66,292.0000 | 169,730,000 | 2.74% | 0.00% |
| Feb. 18, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 6355 | $0.00 | 68,161.0000 | 169,730,000 | 10.28% | 0.00% |
| Feb. 18, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F | Ordinary Shares | 706 | $32.18 | 5,228.0000 | 169,730,000 | 11.90% | 0.00% |
| Feb. 20, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Ordinary Shares | 1872 | $0.00 | 7,100.0000 | 169,730,000 | 35.81% | 0.00% |
| Feb. 20, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Restricted Stock Unit Award | 1872 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| Feb. 20, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F | Ordinary Shares | 641 | $30.39 | 6,459.0000 | 169,730,000 | 9.03% | 0.00% |
| Feb. 18, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Restricted Stock Unit Award | 2034 | $0.00 | 4,067.0000 | 169,730,000 | 33.34% | 0.00% |
| Feb. 18, 2024 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M | Ordinary Shares | 2034 | $0.00 | 5,934.0000 | 169,730,000 | 52.15% | 0.00% |
| Feb. 18, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3951 | $32.18 | 92,883.0000 | 169,730,000 | 4.08% | 0.00% |
| Feb. 18, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 8897 | $0.00 | 96,834.0000 | 169,730,000 | 10.12% | 0.01% |
| Feb. 20, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 4680 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| Feb. 18, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 8897 | $0.00 | 17,793.0000 | 169,730,000 | 33.33% | 0.01% |
| Feb. 20, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 2078 | $30.39 | 147,556.0000 | 169,730,000 | 1.39% | 0.00% |
| Feb. 20, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 4680 | $0.00 | 149,634.0000 | 169,730,000 | 3.23% | 0.00% |
| Feb. 18, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 3888 | $32.18 | 144,954.0000 | 169,730,000 | 2.61% | 0.00% |
| Feb. 18, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 8897 | $0.00 | 148,842.0000 | 169,730,000 | 6.36% | 0.01% |
| Feb. 20, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | M | Ordinary Shares | 4680 | $0.00 | 110,879.0000 | 169,730,000 | 4.41% | 0.00% |
| Feb. 20, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 1725 | $30.39 | 109,154.0000 | 169,730,000 | 1.56% | 0.00% |
| Feb. 18, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | M | Restricted Stock Unit Award | 6355 | $0.00 | 12,709.0000 | 169,730,000 | 33.34% | 0.00% |
| Feb. 20, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | M | Restricted Stock Unit Award | 4680 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| Feb. 20, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 10297 | $0.00 | 103,180.0000 | 169,730,000 | 11.09% | 0.01% |
| Feb. 18, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 8897 | $0.00 | 17,793.0000 | 169,730,000 | 33.33% | 0.01% |
| Feb. 20, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 4572 | $30.39 | 98,608.0000 | 169,730,000 | 4.43% | 0.00% |
| Feb. 18, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Restricted Stock Unit Award | 4448 | $0.00 | 8,897.0000 | 169,730,000 | 33.33% | 0.00% |
| Feb. 18, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 1869 | $32.18 | 106,199.0000 | 169,730,000 | 1.73% | 0.00% |
| Feb. 18, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | M | Ordinary Shares | 6355 | $0.00 | 108,068.0000 | 169,730,000 | 6.25% | 0.00% |
| Feb. 20, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 7177 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| Feb. 18, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 6355 | $0.00 | 12,709.0000 | 169,730,000 | 33.34% | 0.00% |
| Feb. 20, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 2994 | $30.39 | 156,376.0000 | 169,730,000 | 1.88% | 0.00% |
| Feb. 20, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 7177 | $0.00 | 159,370.0000 | 169,730,000 | 4.72% | 0.00% |
| Feb. 18, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 1869 | $32.18 | 152,193.0000 | 169,730,000 | 1.21% | 0.00% |
| Feb. 18, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 6355 | $0.00 | 154,062.0000 | 169,730,000 | 4.30% | 0.00% |
| Feb. 20, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 10297 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.01% |
| Feb. 15, 2024 | LAURENCIN CATO T | Director | M | Ordinary Shares | 2690 | $22.52 | 17,859.0000 | 169,730,000 | 17.73% | 0.00% |
| Feb. 15, 2024 | LAURENCIN CATO T | Director | S | Ordinary Shares | 2690 | $31.85 | 15,169.0000 | 169,730,000 | 15.06% | 0.00% |
| Feb. 15, 2024 | LAURENCIN CATO T | Director | M | Non Qualified Stock Option (Right to Buy) | 2690 | $0.00 | 18,833.0000 | 169,730,000 | 12.50% | 0.00% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Restricted Stock Unit Award | 523 | $0.00 | 26,690.0000 | 163,742,000 | 2.00% | 0.00% |
| Feb. 10, 2024 | MCKEON BRIAN P | Director | M | Ordinary Shares | 4533 | $0.00 | 34,229.0000 | 169,730,000 | 15.26% | 0.00% |
| Feb. 10, 2024 | MCKEON BRIAN P | Director | F | Ordinary Shares | 1088 | $27.32 | 33,141.0000 | 169,730,000 | 3.18% | 0.00% |
| Nov. 17, 2023 | MCKEON BRIAN P | Director | J | Non Qualified Stock Option (Right to Buy) | 90 | $22.48 | 4,639.0000 | 163,742,000 | 1.98% | 0.00% |
| Nov. 17, 2023 | MCKEON BRIAN P | Director | J | Non Qualified Stock Option (Right to Buy) | 523 | $22.48 | 26,692.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | MCKEON BRIAN P | Director | J | Restricted Stock Unit Award | 88 | $0.00 | 4,533.0000 | 163,742,000 | 1.98% | 0.00% |
| Nov. 17, 2023 | MCKEON BRIAN P | Director | J | Non Qualified Stock Option (Right to Buy) | 313 | $24.24 | 15,990.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | MCKEON BRIAN P | Director | J | Non Qualified Stock Option (Right to Buy) | 231 | $30.86 | 11,785.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | MCKEON BRIAN P | Director | J | Non Qualified Stock Option (Right to Buy) | 254 | $30.72 | 12,986.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | MCKEON BRIAN P | Director | J | Restricted Stock Unit Award | 119 | $0.00 | 6,104.0000 | 163,742,000 | 1.99% | 0.00% |
| Feb. 10, 2024 | MCKEON BRIAN P | Director | M | Restricted Stock Unit Award | 4533 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| Feb. 10, 2024 | Daglio David Angelo Jr. | Director | M | Ordinary Shares | 4533 | $0.00 | 104,229.0000 | 169,730,000 | 4.55% | 0.00% |
| Feb. 10, 2024 | Daglio David Angelo Jr. | Director | F | Ordinary Shares | 1088 | $27.32 | 103,141.0000 | 169,730,000 | 1.04% | 0.00% |
| Nov. 17, 2023 | Daglio David Angelo Jr. | Director | J | Non Qualified Stock Option (Right to Buy) | 90 | $22.48 | 4,639.0000 | 163,742,000 | 1.98% | 0.00% |
| Nov. 17, 2023 | Daglio David Angelo Jr. | Director | J | Non Qualified Stock Option (Right to Buy) | 523 | $22.48 | 26,692.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Daglio David Angelo Jr. | Director | J | Restricted Stock Unit Award | 88 | $0.00 | 4,533.0000 | 163,742,000 | 1.98% | 0.00% |
| Nov. 17, 2023 | Daglio David Angelo Jr. | Director | J | Non Qualified Stock Option (Right to Buy) | 313 | $24.24 | 15,990.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Daglio David Angelo Jr. | Director | J | Non Qualified Stock Option (Right to Buy) | 231 | $30.86 | 11,785.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Daglio David Angelo Jr. | Director | J | Non Qualified Stock Option (Right to Buy) | 254 | $30.72 | 12,986.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Daglio David Angelo Jr. | Director | J | Restricted Stock Unit Award | 119 | $0.00 | 6,104.0000 | 163,742,000 | 1.99% | 0.00% |
| Feb. 10, 2024 | Daglio David Angelo Jr. | Director | M | Restricted Stock Unit Award | 4533 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| Feb. 8, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | A | Ordinary Shares | 36835 | $0.00 | 150,952.0000 | 169,730,000 | 32.28% | 0.02% |
| Feb. 8, 2024 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 11007 | $26.77 | 139,945.0000 | 169,730,000 | 7.29% | 0.01% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Employee Stock Option (Right to Buy) | 599 | $46.24 | 30,599.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Employee Stock Option (Right to Buy) | 469 | $69.83 | 23,969.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Employee Stock Option (Right to Buy) | 899 | $31.64 | 45,899.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Employee Stock Option (Right to Buy) | 699 | $53.50 | 35,699.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Employee Stock Option (Right to Buy) | 759 | $65.94 | 38,759.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Employee Stock Option (Right to Buy) | 1489 | $31.93 | 75,989.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Employee Stock Option (Right to Buy) | 1534 | $20.03 | 78,287.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Restricted Stock Unit Award | 91 | $0.00 | 4,680.0000 | 163,742,000 | 1.98% | 0.00% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Employee Stock Option (Right to Buy) | 3102 | $19.34 | 158,221.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Restricted Stock Unit Award | 380 | $0.00 | 19,387.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Employee Stock Option (Right to Buy) | 2790 | $24.59 | 142,344.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Employee Stock Option (Right to Buy) | 2741 | $26.82 | 139,803.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | J | Restricted Stock Unit Award | 685 | $0.00 | 34,951.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Restricted Stock Unit Award | 373 | $0.00 | 19,064.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 499 | $46.24 | 25,499.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 354 | $69.83 | 18,104.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 719 | $31.64 | 36,719.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 799 | $53.50 | 40,799.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 1089 | $65.94 | 55,589.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 2133 | $31.93 | 108,833.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 2352 | $20.03 | 120,040.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Restricted Stock Unit Award | 140 | $0.00 | 7,177.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 2378 | $19.34 | 121,303.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Restricted Stock Unit Award | 291 | $0.00 | 14,863.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 1992 | $24.59 | 101,674.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 576 | $24.82 | 29,388.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Restricted Stock Unit Award | 456 | $0.00 | 23,300.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Employee Stock Option (Right to Buy) | 1827 | $26.82 | 93,202.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Restricted Stock Unit Award | 373 | $0.00 | 19,064.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Employee Stock Option (Right to Buy) | 1992 | $24.59 | 101,674.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Restricted Stock Unit Award | 278 | $0.00 | 14,217.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Employee Stock Option (Right to Buy) | 2274 | $19.34 | 116,028.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Restricted Stock Unit Award | 91 | $0.00 | 4,680.0000 | 163,742,000 | 1.98% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Employee Stock Option (Right to Buy) | 1534 | $20.03 | 78,287.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Employee Stock Option (Right to Buy) | 1489 | $31.93 | 75,989.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Employee Stock Option (Right to Buy) | 759 | $65.94 | 38,759.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Employee Stock Option (Right to Buy) | 799 | $53.50 | 40,799.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Employee Stock Option (Right to Buy) | 719 | $31.64 | 36,719.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Employee Stock Option (Right to Buy) | 354 | $69.83 | 18,104.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | J | Employee Stock Option (Right to Buy) | 499 | $46.24 | 25,499.0000 | 163,742,000 | 2.00% | 0.00% |
| Feb. 8, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 8137 | $26.77 | 101,713.0000 | 169,730,000 | 7.41% | 0.00% |
| Feb. 8, 2024 | Brown Iain Michael | SVP, Chief Financial Officer | A | Ordinary Shares | 27012 | $0.00 | 109,850.0000 | 169,730,000 | 32.61% | 0.02% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Restricted Stock Unit Award | 603 | $0.00 | 30,757.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Employee Stock Option (Right to Buy) | 2412 | $26.82 | 123,027.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | J | Restricted Stock Unit Award | 118 | $0.00 | 6,043.0000 | 163,742,000 | 1.99% | 0.00% |
| Feb. 8, 2024 | POPS RICHARD F | Director and CEO, Alkermes plc | A | Ordinary Shares | 218551 | $0.00 | 1,271,432.0000 | 169,730,000 | 20.76% | 0.13% |
| Feb. 8, 2024 | POPS RICHARD F | Director and CEO, Alkermes plc | F | Ordinary Shares | 91757 | $26.77 | 1,179,675.0000 | 169,730,000 | 7.22% | 0.05% |
| Feb. 8, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | A | Ordinary Shares | 27012 | $0.00 | 69,941.0000 | 169,730,000 | 62.92% | 0.02% |
| Feb. 8, 2024 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 8135 | $26.77 | 61,806.0000 | 169,730,000 | 11.63% | 0.00% |
| Feb. 8, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | A | Ordinary Shares | 21485 | $0.00 | 271,927.0000 | 169,730,000 | 8.58% | 0.01% |
| Feb. 8, 2024 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | F | Ordinary Shares | 3183 | $26.77 | 268,744.0000 | 169,730,000 | 1.17% | 0.00% |
| Feb. 8, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Ordinary Shares | 46658 | $0.00 | 103,217.0000 | 169,730,000 | 82.49% | 0.03% |
| Feb. 8, 2024 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 15280 | $26.77 | 87,937.0000 | 169,730,000 | 14.80% | 0.01% |
| Nov. 17, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 1599 | $58.40 | 81,599.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 1089 | $65.94 | 55,589.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 2133 | $31.93 | 108,833.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 3376 | $20.03 | 172,232.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Restricted Stock Unit Award | 201 | $0.00 | 10,297.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 3929 | $19.34 | 200,413.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Restricted Stock Unit Award | 481 | $0.00 | 24,557.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 2790 | $24.59 | 142,344.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Restricted Stock Unit Award | 523 | $0.00 | 26,690.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 2412 | $26.82 | 123,027.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Restricted Stock Unit Award | 603 | $0.00 | 30,757.0000 | 163,742,000 | 2.00% | 0.00% |
| Feb. 8, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | A | Ordinary Shares | 28240 | $0.00 | 156,190.0000 | 169,730,000 | 22.07% | 0.02% |
| Feb. 8, 2024 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 8483 | $26.77 | 147,707.0000 | 169,730,000 | 5.43% | 0.00% |
| Dec. 8, 2023 | LAURENCIN CATO T | Director | M | Ordinary Shares | 4163 | $0.00 | 16,169.0000 | 163,742,000 | 34.67% | 0.00% |
| Nov. 17, 2023 | LAURENCIN CATO T | Director | J | Non Qualified Stock Option (Right to Buy) | 422 | $22.52 | 21,523.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | LAURENCIN CATO T | Director | J | Non Qualified Stock Option (Right to Buy) | 112 | $22.52 | 5,712.0000 | 163,742,000 | 2.00% | 0.00% |
| Dec. 8, 2023 | LAURENCIN CATO T | Director | F | Ordinary Shares | 1000 | $25.86 | 15,169.0000 | 163,742,000 | 6.18% | 0.00% |
| Dec. 8, 2023 | LAURENCIN CATO T | Director | M | Restricted Stock Unit Award | 4163 | $0.00 | 4,163.0000 | 163,742,000 | 50.00% | 0.00% |
| Nov. 17, 2023 | LAURENCIN CATO T | Director | J | Restricted Stock Unit Award | 163 | $0.00 | 8,326.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | LAURENCIN CATO T | Director | J | Restricted Stock Unit Award | 119 | $0.00 | 6,104.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | LAURENCIN CATO T | Director | J | Non Qualified Stock Option (Right to Buy) | 254 | $30.72 | 12,986.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | LAURENCIN CATO T | Director | J | Non Qualified Stock Option (Right to Buy) | 231 | $30.86 | 11,785.0000 | 163,742,000 | 2.00% | 0.00% |
| Aug. 3, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 877 | $27.63 | 127,950.0000 | 163,742,000 | 0.68% | 0.00% |
| Aug. 3, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 1974 | $0.00 | 128,827.0000 | 163,742,000 | 1.56% | 0.00% |
| Aug. 3, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 1974 | $0.00 | 5,925.0000 | 163,742,000 | 24.99% | 0.00% |
| July 7, 2023 | Wright Christopher I | Director | F | Ordinary Shares | 1430 | $29.88 | 7,269.0000 | 163,742,000 | 16.44% | 0.00% |
| July 7, 2023 | Wysenski Nancy | Director | M | Ordinary Shares | 5957 | $0.00 | 33,028.0000 | 163,742,000 | 22.01% | 0.00% |
| July 7, 2023 | Wysenski Nancy | Director | F | Ordinary Shares | 1430 | $29.88 | 31,598.0000 | 163,742,000 | 4.33% | 0.00% |
| July 7, 2023 | Wysenski Nancy | Director | M | Restricted Stock Unit Award | 5957 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| July 7, 2023 | Wright Christopher I | Director | M | Ordinary Shares | 5957 | $0.00 | 8,699.0000 | 163,742,000 | 217.25% | 0.00% |
| July 7, 2023 | Wright Christopher I | Director | M | Restricted Stock Unit Award | 5957 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| July 7, 2023 | Wilson Frank Anders | Director | M | Ordinary Shares | 5957 | $0.00 | 21,786.0000 | 163,742,000 | 37.63% | 0.00% |
| July 7, 2023 | Wilson Frank Anders | Director | F | Ordinary Shares | 1430 | $29.88 | 20,356.0000 | 163,742,000 | 6.56% | 0.00% |
| July 7, 2023 | Wilson Frank Anders | Director | M | Restricted Stock Unit Award | 5957 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| July 7, 2023 | snyderman nancy lynn MD | Director | M | Ordinary Shares | 5957 | $0.00 | 22,213.0000 | 163,742,000 | 36.64% | 0.00% |
| July 7, 2023 | snyderman nancy lynn MD | Director | F | Ordinary Shares | 1430 | $29.88 | 20,783.0000 | 163,742,000 | 6.44% | 0.00% |
| July 7, 2023 | snyderman nancy lynn MD | Director | M | Restricted Stock Unit Award | 5957 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| July 7, 2023 | MCKEON BRIAN P | Director | M | Ordinary Shares | 5957 | $0.00 | 31,126.0000 | 163,742,000 | 23.67% | 0.00% |
| July 7, 2023 | MCKEON BRIAN P | Director | F | Ordinary Shares | 1430 | $29.88 | 29,696.0000 | 163,742,000 | 4.59% | 0.00% |
| July 7, 2023 | MCKEON BRIAN P | Director | M | Restricted Stock Unit Award | 5957 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| July 7, 2023 | LAURENCIN CATO T | Director | M | Ordinary Shares | 5957 | $0.00 | 13,436.0000 | 163,742,000 | 79.65% | 0.00% |
| July 7, 2023 | LAURENCIN CATO T | Director | F | Ordinary Shares | 1430 | $29.88 | 12,006.0000 | 163,742,000 | 10.64% | 0.00% |
| July 7, 2023 | LAURENCIN CATO T | Director | M | Restricted Stock Unit Award | 5957 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| July 7, 2023 | GAYNOR RICHARD | Director | M | Ordinary Shares | 5957 | $0.00 | 21,786.0000 | 163,742,000 | 37.63% | 0.00% |
| July 7, 2023 | GAYNOR RICHARD | Director | F | Ordinary Shares | 1430 | $29.88 | 20,356.0000 | 163,742,000 | 6.56% | 0.00% |
| July 7, 2023 | GAYNOR RICHARD | Director | M | Restricted Stock Unit Award | 5957 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| July 7, 2023 | Daglio David Angelo Jr. | Director | M | Ordinary Shares | 5957 | $0.00 | 101,126.0000 | 163,742,000 | 6.26% | 0.00% |
| July 7, 2023 | Daglio David Angelo Jr. | Director | F | Ordinary Shares | 1430 | $29.88 | 99,696.0000 | 163,742,000 | 1.41% | 0.00% |
| July 7, 2023 | Daglio David Angelo Jr. | Director | M | Restricted Stock Unit Award | 5957 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| July 7, 2023 | Cooke Shane | Director | M | Ordinary Shares | 5957 | $0.00 | 100,075.0000 | 163,742,000 | 6.33% | 0.00% |
| July 7, 2023 | Cooke Shane | Director | F | Ordinary Shares | 3098 | $29.88 | 96,977.0000 | 163,742,000 | 3.10% | 0.00% |
| July 7, 2023 | Cooke Shane | Director | M | Restricted Stock Unit Award | 5957 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| July 7, 2023 | Alva Emily Peterson | Director | M | Ordinary Shares | 5957 | $0.00 | 21,152.0000 | 163,742,000 | 39.20% | 0.00% |
| July 7, 2023 | Alva Emily Peterson | Director | F | Ordinary Shares | 1430 | $29.88 | 19,722.0000 | 163,742,000 | 6.76% | 0.00% |
| July 7, 2023 | Alva Emily Peterson | Director | M | Restricted Stock Unit Award | 5957 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| June 29, 2023 | LAURENCIN CATO T | Director | A | Non Qualified Stock Option (Right to Buy) | 12732 | $0.00 | 12,732.0000 | 163,742,000 | 9999.99% | 0.01% |
| June 29, 2023 | LAURENCIN CATO T | Director | A | Restricted Stock Unit Award | 5985 | $0.00 | 5,985.0000 | 163,742,000 | 9999.99% | 0.00% |
| June 29, 2023 | snyderman nancy lynn MD | Director | A | Restricted Stock Unit Award | 5985 | $0.00 | 5,985.0000 | 163,742,000 | 9999.99% | 0.00% |
| June 29, 2023 | GAYNOR RICHARD | Director | A | Restricted Stock Unit Award | 5985 | $0.00 | 5,985.0000 | 163,742,000 | 9999.99% | 0.00% |
| June 29, 2023 | Wysenski Nancy | Director | A | Non Qualified Stock Option (Right to Buy) | 12732 | $0.00 | 12,732.0000 | 163,742,000 | 9999.99% | 0.01% |
| June 29, 2023 | Wysenski Nancy | Director | A | Restricted Stock Unit Award | 5985 | $0.00 | 5,985.0000 | 163,742,000 | 9999.99% | 0.00% |
| June 29, 2023 | GAYNOR RICHARD | Director | A | Non Qualified Stock Option (Right to Buy) | 12732 | $0.00 | 12,732.0000 | 163,742,000 | 9999.99% | 0.01% |
| June 29, 2023 | Wright Christopher I | Director | A | Non Qualified Stock Option (Right to Buy) | 12732 | $0.00 | 12,732.0000 | 163,742,000 | 9999.99% | 0.01% |
| June 29, 2023 | Wright Christopher I | Director | A | Restricted Stock Unit Award | 5985 | $0.00 | 5,985.0000 | 163,742,000 | 9999.99% | 0.00% |
| June 29, 2023 | Wilson Frank Anders | Director | A | Non Qualified Stock Option (Right to Buy) | 12732 | $0.00 | 12,732.0000 | 163,742,000 | 9999.99% | 0.01% |
| June 29, 2023 | Wilson Frank Anders | Director | A | Restricted Stock Unit Award | 5985 | $0.00 | 5,985.0000 | 163,742,000 | 9999.99% | 0.00% |
| June 29, 2023 | snyderman nancy lynn MD | Director | A | Non Qualified Stock Option (Right to Buy) | 12732 | $0.00 | 12,732.0000 | 163,742,000 | 9999.99% | 0.01% |
| June 29, 2023 | Alva Emily Peterson | Director | A | Non Qualified Stock Option (Right to Buy) | 12732 | $0.00 | 12,732.0000 | 163,742,000 | 9999.99% | 0.01% |
| June 29, 2023 | Daglio David Angelo Jr. | Director | A | Non Qualified Stock Option (Right to Buy) | 12732 | $0.00 | 12,732.0000 | 163,742,000 | 9999.99% | 0.01% |
| June 29, 2023 | Cooke Shane | Director | A | Restricted Stock Unit Award | 5985 | $0.00 | 5,985.0000 | 163,742,000 | 9999.99% | 0.00% |
| June 29, 2023 | Cooke Shane | Director | A | Non Qualified Stock Option (Right to Buy) | 12732 | $0.00 | 12,732.0000 | 163,742,000 | 9999.99% | 0.01% |
| June 29, 2023 | Daglio David Angelo Jr. | Director | A | Restricted Stock Unit Award | 5985 | $0.00 | 5,985.0000 | 163,742,000 | 9999.99% | 0.00% |
| June 29, 2023 | MCKEON BRIAN P | Director | A | Restricted Stock Unit Award | 5985 | $0.00 | 5,985.0000 | 163,742,000 | 9999.99% | 0.00% |
| June 29, 2023 | MCKEON BRIAN P | Director | A | Non Qualified Stock Option (Right to Buy) | 12732 | $0.00 | 12,732.0000 | 163,742,000 | 9999.99% | 0.01% |
| June 29, 2023 | Alva Emily Peterson | Director | A | Restricted Stock Unit Award | 5985 | $0.00 | 5,985.0000 | 163,742,000 | 9999.99% | 0.00% |
| June 9, 2023 | Alva Emily Peterson | Director | M | Restricted Stock Unit Award | 3795 | $0.00 | 3,796.0000 | 163,742,000 | 49.99% | 0.00% |
| June 8, 2023 | Wright Christopher I | Director | M | Restricted Stock Unit Award | 3236 | $0.00 | 6,473.0000 | 163,742,000 | 33.33% | 0.00% |
| June 8, 2023 | Wright Christopher I | Director | M | Restricted Stock Unit Award | 373 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| June 8, 2023 | Wright Christopher I | Director | F | Ordinary Shares | 777 | $31.54 | 2,742.0000 | 163,742,000 | 22.08% | 0.00% |
| June 8, 2023 | Wright Christopher I | Director | M | Ordinary Shares | 3236 | $0.00 | 3,519.0000 | 163,742,000 | 1143.46% | 0.00% |
| June 8, 2023 | Wright Christopher I | Director | F | Ordinary Shares | 90 | $31.54 | 283.0000 | 163,742,000 | 24.13% | 0.00% |
| June 8, 2023 | Wright Christopher I | Director | M | Ordinary Shares | 373 | $0.00 | 373.0000 | 163,742,000 | 9999.99% | 0.00% |
| June 9, 2023 | Alva Emily Peterson | Director | F | Ordinary Shares | 911 | $31.13 | 15,195.0000 | 163,742,000 | 5.66% | 0.00% |
| June 9, 2023 | Alva Emily Peterson | Director | M | Ordinary Shares | 3795 | $0.00 | 16,106.0000 | 163,742,000 | 30.83% | 0.00% |
| June 8, 2023 | LAURENCIN CATO T | Director | M | Non Qualified Stock Option (Right to Buy) | 2638 | $0.00 | 21,101.0000 | 163,742,000 | 11.11% | 0.00% |
| June 8, 2023 | LAURENCIN CATO T | Director | M | Ordinary Shares | 2638 | $22.97 | 10,117.0000 | 163,742,000 | 35.27% | 0.00% |
| June 8, 2023 | LAURENCIN CATO T | Director | S | Ordinary Shares | 2638 | $31.85 | 7,479.0000 | 163,742,000 | 26.07% | 0.00% |
| June 7, 2023 | LAURENCIN CATO T | Director | M | Non Qualified Stock Option (Right to Buy) | 2800 | $0.00 | 5,600.0000 | 163,742,000 | 33.33% | 0.00% |
| June 7, 2023 | LAURENCIN CATO T | Director | S | Ordinary Shares | 2800 | $31.50 | 7,479.0000 | 163,742,000 | 27.24% | 0.00% |
| June 7, 2023 | LAURENCIN CATO T | Director | M | Ordinary Shares | 2800 | $22.97 | 10,279.0000 | 163,742,000 | 37.44% | 0.00% |
| June 5, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 3500 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| June 5, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 1555 | $29.46 | 42,929.0000 | 163,742,000 | 3.50% | 0.00% |
| June 5, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 3500 | $0.00 | 44,484.0000 | 163,742,000 | 8.54% | 0.00% |
| May 30, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Employee Stock Option (Right to Buy) | 19634 | $0.00 | 44,327.0000 | 163,742,000 | 30.70% | 0.01% |
| May 30, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 19634 | $20.43 | 68,118.0000 | 163,742,000 | 40.50% | 0.01% |
| May 30, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | S | Ordinary Shares | 27134 | $28.93 | 40,984.0000 | 163,742,000 | 39.83% | 0.02% |
| May 9, 2023 | Wysenski Nancy | Director | M | Non Qualified Stock Option (Right to Buy) | 35000 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.02% |
| May 9, 2023 | Wysenski Nancy | Director | M | Ordinary Shares | 35000 | $31.13 | 62,071.0000 | 163,742,000 | 129.29% | 0.02% |
| May 9, 2023 | Wysenski Nancy | Director | M | Ordinary Shares | 6250 | $31.13 | 68,321.0000 | 163,742,000 | 10.07% | 0.00% |
| May 9, 2023 | Wysenski Nancy | Director | S | Ordinary Shares | 41250 | $31.24 | 27,071.0000 | 163,742,000 | 60.38% | 0.03% |
| May 9, 2023 | Wysenski Nancy | Director | M | Non Qualified Stock Option (Right to Buy) | 6250 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| Feb. 22, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 2704 | $27.77 | 48,484.0000 | 163,742,000 | 5.28% | 0.00% |
| Feb. 23, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | A | Employee Stock Option (Right to Buy) | 284873 | $0.00 | 284,873.0000 | 163,742,000 | 9999.99% | 0.17% |
| Feb. 22, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 6969 | $0.00 | 51,188.0000 | 163,742,000 | 15.76% | 0.00% |
| Feb. 22, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 6969 | $0.00 | 13,939.0000 | 163,742,000 | 33.33% | 0.00% |
| Feb. 23, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | A | Restricted Stock Unit Award | 22844 | $0.00 | 22,844.0000 | 163,742,000 | 9999.99% | 0.01% |
| Feb. 23, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | A | Employee Stock Option (Right to Buy) | 91375 | $0.00 | 91,375.0000 | 163,742,000 | 9999.99% | 0.06% |
| Feb. 22, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | M | Restricted Stock Unit Award | 6969 | $0.00 | 13,939.0000 | 163,742,000 | 33.33% | 0.00% |
| Feb. 22, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 2049 | $27.77 | 82,838.0000 | 163,742,000 | 2.41% | 0.00% |
| Feb. 22, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | M | Ordinary Shares | 6969 | $0.00 | 84,887.0000 | 163,742,000 | 8.94% | 0.00% |
| Feb. 23, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | A | Restricted Stock Unit Award | 30154 | $0.00 | 30,154.0000 | 163,742,000 | 9999.99% | 0.02% |
| Feb. 23, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | A | Employee Stock Option (Right to Buy) | 120615 | $0.00 | 120,615.0000 | 163,742,000 | 9999.99% | 0.07% |
| Feb. 22, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 7286 | $0.00 | 14,572.0000 | 163,742,000 | 33.33% | 0.00% |
| Feb. 22, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 3224 | $27.77 | 126,853.0000 | 163,742,000 | 2.48% | 0.00% |
| Feb. 22, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 7286 | $0.00 | 130,077.0000 | 163,742,000 | 5.93% | 0.00% |
| Feb. 23, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Restricted Stock Unit Award | 30154 | $0.00 | 30,154.0000 | 163,742,000 | 9999.99% | 0.02% |
| Feb. 23, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Employee Stock Option (Right to Buy) | 120615 | $0.00 | 120,615.0000 | 163,742,000 | 9999.99% | 0.07% |
| Feb. 22, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 12038 | $0.00 | 24,076.0000 | 163,742,000 | 33.33% | 0.01% |
| Feb. 22, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 5345 | $27.77 | 56,559.0000 | 163,742,000 | 8.63% | 0.00% |
| Feb. 22, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12038 | $0.00 | 61,904.0000 | 163,742,000 | 24.14% | 0.01% |
| Feb. 23, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | A | Restricted Stock Unit Award | 34266 | $0.00 | 34,266.0000 | 163,742,000 | 9999.99% | 0.02% |
| Feb. 23, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | A | Employee Stock Option (Right to Buy) | 137062 | $0.00 | 137,062.0000 | 163,742,000 | 9999.99% | 0.08% |
| Feb. 22, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 9504 | $0.00 | 19,007.0000 | 163,742,000 | 33.33% | 0.01% |
| Feb. 22, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 3088 | $27.77 | 114,117.0000 | 163,742,000 | 2.63% | 0.00% |
| Feb. 22, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 9504 | $0.00 | 117,205.0000 | 163,742,000 | 8.82% | 0.01% |
| Feb. 23, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | A | Restricted Stock Unit Award | 15991 | $0.00 | 15,991.0000 | 163,742,000 | 9999.99% | 0.01% |
| Feb. 23, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | A | Employee Stock Option (Right to Buy) | 63962 | $0.00 | 63,962.0000 | 163,742,000 | 9999.99% | 0.04% |
| Feb. 22, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Restricted Stock Unit Award | 5544 | $0.00 | 11,088.0000 | 163,742,000 | 33.33% | 0.00% |
| Feb. 22, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | F | Ordinary Shares | 2462 | $27.77 | 250,442.0000 | 163,742,000 | 0.97% | 0.00% |
| Feb. 22, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Ordinary Shares | 5544 | $0.00 | 252,904.0000 | 163,742,000 | 2.24% | 0.00% |
| Feb. 23, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | A | Restricted Stock Unit Award | 25128 | $0.00 | 25,128.0000 | 163,742,000 | 9999.99% | 0.02% |
| Feb. 23, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | A | Employee Stock Option (Right to Buy) | 100512 | $0.00 | 100,512.0000 | 163,742,000 | 9999.99% | 0.06% |
| Feb. 20, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 10095 | $0.00 | 34,155.0000 | 163,742,000 | 41.96% | 0.01% |
| Feb. 18, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 2656 | $28.07 | 24,060.0000 | 163,742,000 | 9.94% | 0.00% |
| Feb. 18, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 8722 | $0.00 | 26,716.0000 | 163,742,000 | 48.47% | 0.01% |
| Feb. 21, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 4800 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| Feb. 20, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 4589 | $0.00 | 4,589.0000 | 163,742,000 | 50.00% | 0.00% |
| Feb. 18, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Restricted Stock Unit Award | 8722 | $0.00 | 26,167.0000 | 163,742,000 | 25.00% | 0.01% |
| Feb. 21, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 1412 | $27.77 | 107,701.0000 | 163,742,000 | 1.29% | 0.00% |
| Feb. 21, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 4800 | $0.00 | 109,113.0000 | 163,742,000 | 4.60% | 0.00% |
| Feb. 20, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 2966 | $28.07 | 104,313.0000 | 163,742,000 | 2.76% | 0.00% |
| Feb. 20, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | A | Ordinary Shares | 10086 | $0.00 | 107,279.0000 | 163,742,000 | 10.38% | 0.01% |
| Feb. 20, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 1350 | $28.07 | 97,193.0000 | 163,742,000 | 1.37% | 0.00% |
| Feb. 20, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 4589 | $0.00 | 98,543.0000 | 163,742,000 | 4.88% | 0.00% |
| Feb. 18, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | F | Ordinary Shares | 2683 | $28.07 | 93,954.0000 | 163,742,000 | 2.78% | 0.00% |
| Feb. 18, 2023 | Jackson Blair Curtis | EVP, Chief Operating Officer | M | Ordinary Shares | 8722 | $0.00 | 96,637.0000 | 163,742,000 | 9.92% | 0.01% |
| Feb. 21, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Restricted Stock Unit Award | 5825 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| Feb. 20, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Restricted Stock Unit Award | 5354 | $0.00 | 5,354.0000 | 163,742,000 | 50.00% | 0.00% |
| Feb. 18, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Restricted Stock Unit Award | 4361 | $0.00 | 13,084.0000 | 163,742,000 | 25.00% | 0.00% |
| Feb. 21, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | F | Ordinary Shares | 2587 | $27.77 | 247,360.0000 | 163,742,000 | 1.04% | 0.00% |
| Feb. 21, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Ordinary Shares | 5825 | $0.00 | 249,947.0000 | 163,742,000 | 2.39% | 0.00% |
| Feb. 20, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | F | Ordinary Shares | 5226 | $28.07 | 244,122.0000 | 163,742,000 | 2.10% | 0.00% |
| Feb. 20, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | A | Ordinary Shares | 11770 | $0.00 | 249,348.0000 | 163,742,000 | 4.95% | 0.01% |
| Feb. 20, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | F | Ordinary Shares | 2378 | $28.07 | 237,578.0000 | 163,742,000 | 0.99% | 0.00% |
| Feb. 20, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Ordinary Shares | 5354 | $0.00 | 239,956.0000 | 163,742,000 | 2.28% | 0.00% |
| Feb. 18, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | F | Ordinary Shares | 2065 | $28.07 | 234,602.0000 | 163,742,000 | 0.87% | 0.00% |
| Feb. 18, 2023 | LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | M | Ordinary Shares | 4361 | $0.00 | 236,667.0000 | 163,742,000 | 1.88% | 0.00% |
| Feb. 20, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 3824 | $0.00 | 3,825.0000 | 163,742,000 | 49.99% | 0.00% |
| Feb. 18, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Restricted Stock Unit Award | 6230 | $0.00 | 18,691.0000 | 163,742,000 | 25.00% | 0.00% |
| Feb. 20, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 6753 | $28.07 | 44,219.0000 | 163,742,000 | 13.25% | 0.00% |
| Feb. 20, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | A | Ordinary Shares | 22969 | $0.00 | 50,972.0000 | 163,742,000 | 82.02% | 0.01% |
| Feb. 20, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 3824 | $0.00 | 29,128.0000 | 163,742,000 | 15.11% | 0.00% |
| Feb. 18, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 1961 | $28.07 | 25,304.0000 | 163,742,000 | 7.19% | 0.00% |
| Feb. 18, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | M | Ordinary Shares | 6230 | $0.00 | 27,265.0000 | 163,742,000 | 29.62% | 0.00% |
| Feb. 21, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | M | Restricted Stock Unit Award | 32400 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.02% |
| Feb. 21, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | F | Ordinary Shares | 14386 | $27.77 | 1,052,881.0000 | 163,742,000 | 1.35% | 0.01% |
| Feb. 21, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | M | Ordinary Shares | 32400 | $0.00 | 1,067,267.0000 | 163,742,000 | 3.13% | 0.02% |
| Feb. 20, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | F | Ordinary Shares | 53145 | $28.07 | 1,034,867.0000 | 163,742,000 | 4.88% | 0.03% |
| Feb. 20, 2023 | POPS RICHARD F | Director and CEO, Alkermes plc | A | Ordinary Shares | 119713 | $0.00 | 1,088,012.0000 | 163,742,000 | 12.36% | 0.07% |
| Feb. 20, 2023 | Nichols Christian Todd | SVP, Chief Commercial Officer | F | Ordinary Shares | 1125 | $28.07 | 28,003.0000 | 163,742,000 | 3.86% | 0.00% |
| Feb. 21, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | M | Restricted Stock Unit Award | 4800 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| Feb. 20, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | M | Restricted Stock Unit Award | 4589 | $0.00 | 4,589.0000 | 163,742,000 | 50.00% | 0.00% |
| Feb. 18, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | M | Restricted Stock Unit Award | 6230 | $0.00 | 18,691.0000 | 163,742,000 | 25.00% | 0.00% |
| Feb. 21, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 1412 | $27.77 | 77,918.0000 | 163,742,000 | 1.78% | 0.00% |
| Feb. 21, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | M | Ordinary Shares | 4800 | $0.00 | 79,330.0000 | 163,742,000 | 6.44% | 0.00% |
| Feb. 20, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 2966 | $28.07 | 74,530.0000 | 163,742,000 | 3.83% | 0.00% |
| Feb. 20, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | A | Ordinary Shares | 10086 | $0.00 | 77,496.0000 | 163,742,000 | 14.96% | 0.01% |
| Feb. 20, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 1350 | $28.07 | 67,410.0000 | 163,742,000 | 1.96% | 0.00% |
| Feb. 20, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | M | Ordinary Shares | 4589 | $0.00 | 68,760.0000 | 163,742,000 | 7.15% | 0.00% |
| Feb. 18, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | F | Ordinary Shares | 1965 | $28.07 | 64,171.0000 | 163,742,000 | 2.97% | 0.00% |
| Feb. 18, 2023 | Brown Iain Michael | SVP, Chief Financial Officer | M | Ordinary Shares | 6230 | $0.00 | 66,136.0000 | 163,742,000 | 10.40% | 0.00% |
| Feb. 21, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 6875 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| Feb. 20, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 7036 | $0.00 | 7,037.0000 | 163,742,000 | 50.00% | 0.00% |
| Feb. 18, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Restricted Stock Unit Award | 6230 | $0.00 | 18,691.0000 | 163,742,000 | 25.00% | 0.00% |
| Feb. 21, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 2022 | $27.77 | 122,791.0000 | 163,742,000 | 1.62% | 0.00% |
| Feb. 21, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 6875 | $0.00 | 124,813.0000 | 163,742,000 | 5.83% | 0.00% |
| Feb. 20, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 4548 | $28.07 | 117,938.0000 | 163,742,000 | 3.71% | 0.00% |
| Feb. 20, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | A | Ordinary Shares | 15468 | $0.00 | 122,486.0000 | 163,742,000 | 14.45% | 0.01% |
| Feb. 20, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 2069 | $28.07 | 107,018.0000 | 163,742,000 | 1.90% | 0.00% |
| Feb. 20, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 7036 | $0.00 | 109,087.0000 | 163,742,000 | 6.89% | 0.00% |
| Feb. 18, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F | Ordinary Shares | 1945 | $28.07 | 102,051.0000 | 163,742,000 | 1.87% | 0.00% |
| Feb. 18, 2023 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M | Ordinary Shares | 6230 | $0.00 | 103,996.0000 | 163,742,000 | 6.37% | 0.00% |
| Feb. 21, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 6875 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| Feb. 20, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 10095 | $0.00 | 10,096.0000 | 163,742,000 | 50.00% | 0.01% |
| Feb. 18, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 8722 | $0.00 | 26,167.0000 | 163,742,000 | 25.00% | 0.01% |
| Feb. 21, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3053 | $27.77 | 49,866.0000 | 163,742,000 | 5.77% | 0.00% |
| Feb. 21, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 6875 | $0.00 | 52,919.0000 | 163,742,000 | 14.93% | 0.00% |
| Feb. 20, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 6526 | $28.07 | 46,044.0000 | 163,742,000 | 12.41% | 0.00% |
| Feb. 20, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Ordinary Shares | 22195 | $0.00 | 52,570.0000 | 163,742,000 | 73.07% | 0.01% |
| Feb. 20, 2023 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3780 | $28.07 | 30,375.0000 | 163,742,000 | 11.07% | 0.00% |
| Feb. 10, 2023 | Daglio David Angelo Jr. | Director | M | Restricted Stock Unit Award | 4445 | $0.00 | 4,445.0000 | 163,742,000 | 50.00% | 0.00% |
| Feb. 10, 2023 | MCKEON BRIAN P | Director | M | Ordinary Shares | 4445 | $0.00 | 25,169.0000 | 163,742,000 | 21.45% | 0.00% |
| Feb. 10, 2023 | MCKEON BRIAN P | Director | M | Restricted Stock Unit Award | 4445 | $0.00 | 4,445.0000 | 163,742,000 | 50.00% | 0.00% |
| Feb. 10, 2023 | Daglio David Angelo Jr. | Director | M | Ordinary Shares | 4445 | $0.00 | 95,169.0000 | 163,742,000 | 4.90% | 0.00% |